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Background: Chronic pelvic pain (CPP) symptoms in women are variable and non-specific; establishing a
differential diagnosis can be hard. A diagnostic laparoscopy is often performed, although a prior magnetic
resonance imaging (MRI) scan may beneficial.
Objectives: To estimate the accuracy and added value of MRI in making diagnoses of (1) idiopathic CPP
and (2) the main gynaecological causes of CPP. To quantify the impact MRI can have on decision-making
with respect to triaging for therapeutic laparoscopy and to conduct an economic evaluation.
Design: Comparative test-accuracy study with cost-effectiveness modelling.
Setting: Twenty-six UK-based hospitals.
Participants: A total of 291 women with CPP.
Methods: Pre-index information concerning the patient’s medical history, previous pelvic examinations and
ultrasound scans was collected. Women reported symptoms and quality of life at baseline and 6 months.
MRI scans and diagnostic laparoscopy (undertaken and interpreted blind to each other) were the index tests.
For each potential cause of CPP, gynaecologists indicated their level of certainty that the condition was
causing the pelvic pain. The analysis considered both diagnostic laparoscopy as a reference standard for
observing structural gynaecological causes and consensus from a two-stage expert independent panel for
ascertaining the cause of CPP. The stage 1 consensus was based on pre-index, laparoscopy and follow-up
DOI: 10.3310/hta22400 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 40
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Khan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
vii
data; for stage 2, the MRI scan report was also provided. The primary analysis involved calculations of
sensitivity and specificity for the presence or absence of each structural gynaecological cause of pain.
A decision-analytic model was developed, with a 6-month time horizon. Two strategies, laparoscopy or MRI,
were considered and populated with study data.
Results: Using reference standards of laparoscopic and expert panel diagnoses, MRI scans had high specificity
but poor sensitivity for observing deep-infiltrating endometriosis, endometrioma, adhesions and ovarian cysts.
MRI scans correctly identified 56% [95% confidence interval (CI) 48% to 64%] of women judged to have
idiopathic CPP, but missed 46% (95% CI 37% to 55%) of those considered to have a gynaecological structural
cause of CPP. MRI added significant value, over and above the pre-index information, in identifying deep-
infiltrating endometriosis (p= 0.006) and endometrioma (p = 0.02) as the cause of pain, but not for other
gynaecological structural causes or for identifying idiopathic CPP (p= 0.08). Laparoscopy was significantly more
accurate than MRI in diagnosing idiopathic CPP (p < 0.0001), superficial peritoneal endometriosis (p< 0.0001),
deep-infiltrating endometriosis (p < 0.0001) and endometrioma of the ovary (p = 0.02) as the cause of pelvic
pain. The accuracy of laparoscopy appeared to be able to rule in these diagnoses. Using MRI to identify women
who require therapeutic laparoscopy would lead to 369 women in a cohort of 1000 receiving laparoscopy
unnecessarily, and 136 women who required laparoscopy not receiving it. The economic analysis highlighted
the importance of the time horizon, the prevalence of CPP and the cut-off values to inform the sensitivity and
specificity of MRI and laparoscopy on the model results. MRI was not found to be a cost-effective diagnostic
approach in any scenario.
Conclusions: MRI was dominated by laparoscopy in differential diagnosis of women presenting to
gynaecology clinics with CPP. It did not add value to information already gained from history, examination
and ultrasound about idiopathic CPP and various gynaecological conditions.
Trial registration: Current Controlled Trials ISRCTN13028601.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 40.
See the NIHR Journals Library website for further project information.
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Plain English summary
Chronic pelvic pain (CPP) is pain in the pelvic and lower abdominal region that lasts for 6 months orlonger. It can be caused by a gynaecological condition, such as endometriosis, or by bladder or bowel
conditions. Most women will be offered laparoscopy, a keyhole surgery procedure to examine the inside of
the abdomen, for treatment. Some other conditions can also be treated at the same time. In about half of
all women, no obvious cause can be found for their pain.
Magnetic resonance imaging (MRI) scans can identify painful conditions, but we do not know whether or
not they are better than laparoscopy. We performed a complex study in which nearly 300 women had a
pelvic examination, an ultrasound scan, a MRI scan and then laparoscopy, and also completed symptom
questionnaires. Gynaecologists considered all of this information and gave an opinion on the cause of pain
for each woman. The study concluded that MRI scans could only correctly rule out a gynaecological
condition in half of women judged to have no obvious cause, and missed half of the women who did have
a gynaecological condition. Furthermore, MRI did not help to identify those women who could be treated
during the laparoscopy; for every group of 1000 women with CPP having MRI scans, 369 women would
then have an unnecessary laparoscopy because the MRI scans mistakenly showed a treatable cause,
and 136 women would be incorrectly denied a laparoscopy, when actually there was a treatable cause
that was not seen on the MRI scan. We do not think that all women should have a MRI scan using the
currently available technologies.
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Scientific summary
Background
Chronic pelvic pain (CPP) may be defined as pain in the pelvic and lower abdominal region, that lasts for
≥ 6 months. Idiopathic CPP is defined as CPP with an uncertain or unknown structural cause, after the
exclusion of any other recognisable gynaecological pathology. Conditions such as endometriosis, fibroids,
adenomyosis, cystic ovaries, adhesions and pelvic inflammatory disease are potential gynaecological
causes, although CPP can have origins in the bowel, bladder, pelvic bones, muscles and fascia.
Symptoms experienced in CPP are variable and non-specific, so establishing a differential diagnosis can be
hard. The Royal College of Obstetricians and Gynaecologists guidelines on the management of CPP [Royal
College of Obstetricians and Gynaecologists. Chronic Pelvic Pain, Initial Management (Green-top Guideline
No. 41). London: Royal College of Obstetricians and Gynaecologists; 2012] provide a number of suggested
initial investigations, including history, microbiological screening and vaginal examination, all based on
low-quality evidence. If no cause of the pain is found, a diagnostic laparoscopy is often performed, although
many conditions associated with CPP are not amenable to either laparoscopic diagnosis or treatment.
The aim of the Magnetic resonance imaging to Establish Diagnosis Against Laparoscopy (MEDAL) study was
to assess if magnetic resonance imaging (MRI) can add value in the decision to perform a laparoscopy in
women presenting with CPP. The important question was whether or not a normal MRI scan has a high
enough negative predictive value to replace and avoid laparoscopy.
Objectives
1. To estimate the accuracy of post-MRI diagnoses with respect to (1) the absence of any observed
condition or cause (i.e. idiopathic CPP); and (2) the main gynaecological conditions or causes of CPP
as target conditions, using both post-laparoscopy diagnoses and expert independent panel (EIP)
consensus (with and without incorporating MRI findings) as reference standards.
2. To determine the added value of MRI in a care pathway involving baseline history, clinical examination
and ultrasound before performing laparoscopy.
3. To quantify the impact that pre-laparoscopy MRI scans can have on decision-making, with respect to
triaging for therapeutic laparoscopy.
4. To perform a decision-analytic model-based economic evaluation determining the cost-effectiveness of
MRI compared with laparoscopy.
Methods
We performed a comparative test-accuracy study with panel consensus for determining the reference
standard.
Participants and setting
We recruited women aged ≥ 16 years, who had been referred to a gynaecologist, with CPP of at least
6 months’ duration, and in whom there was an indication for diagnostic laparoscopy, from 26 UK
hospitals. Women were excluded if they had had a hysterectomy, were pregnant, were unable to give
written informed consent, definitely had a clinical indication for a MRI scan or if they had a previously
established cause of CPP. Information concerning menstrual, obstetric and contraceptive history, pelvic
examination and ultrasound scans was collected at baseline. Patient-completed questionnaires captured
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domains such as (1) the location and severity of pain; (2) neuropathic, bowel-, urinary- and endometriosis-
associated pain symptoms; (3) personality characteristics; (4) coping strategies; (5) depression; (6) prior
sexual and physical abuse; and (7) general quality of life. Six months after diagnostic laparoscopy, data
regarding treatments offered were collected and patient questionnaires were repeated.
Index tests
Diagnostic laparoscopy and MRI scans were the index tests. The MRI standard protocol comprised T1
and T2 axial, T2 sagittal, T2 coronal and T1-fast-spin (FS) axial, sagittal and coronal sequences. The
observations were captured on a standardised report form and verified by a second radiologist who was
blind to the initial MRI report. The diagnostic laparoscopy was performed under general anaesthetic in
accordance with the gynaecologist’s standard practice. When clinically indicated, additional therapeutic
and diagnostic procedures were performed at the time of surgery.
To avoid verification bias, MRI was performed before diagnostic laparoscopy, and treating gynaecologists
and investigators were kept blind to the MRI reports and images. To model the impact of using the MRI
scan report, an independent gynaecologist reviewed each case. This gynaecologist was randomly selected
from another hospital recruiting to the MEDAL study.
At several stages in the study path for each patient, the treating gynaecologist and the independent
gynaecologist reviewed the diagnostic evidence available. To establish a possible diagnosis for each target
condition (including idiopathic CPP), the gynaecologists indicated their level of certainty that the condition
was causing the pelvic pain on a numerical rating scale, ranking from 0, meaning no chance, to 10,
meaning certain.
Reference standard
The analysis considered two sets of reference standard. The first set identified was to assess the accuracy
of MRI for observing a condition; the second was to assess the accuracy of MRI for identifying the
condition(s) causing pelvic pain. The first set used findings on laparoscopy for the reference standard;
the second used consensus from an EIP. The consensus process, the target condition definitions and the
data presentation were standardised prior to the panel meetings, and reproducibility was assessed. The
first-stage reference diagnosis was based on patient history and reported symptoms, clinical examination,
ultrasound, laparoscopy and follow-up. For the second-stage reference diagnosis, the MRI scan report was
provided. The panel members selected all conditions for which they were at least 50% certain that these
were the underlying cause.
Sample size
A sample size of 250 women was chosen to address the primary research question of how many women
could have avoided laparoscopy if MRI was routinely used in practice for diagnosing women with CPP.
The study had over 90% power (at p = 0.05) to detect a reduction of 10% in the number of laparoscopies
needed (i.e. from 100% down to 90%). With a prevalence of ≥ 30% of idiopathic CPP, this sample size
had the ability to reliably rule out a sensitivity or specificity of < 70% if the ‘true’ sensitivity or specificity
was > 80%.
Analysis
The prevalence of all gynaecological and non-gynaecological conditions in relation to whether or not they
were believed to be causing pain (as determined by the reference standard established by consensus by
the EIP) was calculated along with 95% confidence intervals (CIs) using binomial exact methods. The
kappa value, alongside the 95% CIs, indicated the agreement between the three individual members of
the EIP in their diagnoses.
The primary analysis involved calculations of sensitivity and specificity (and the associated 95% CIs) for
the presence or absence of each structural gynaecological cause of pain; data were taken from the binary
yes/no responses of the reference standard before and after the MRI data were revealed. Receiver operator
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characteristic curves were also constructed for each test for each condition, using the certainty estimates
provided by the treating gynaecologists and the independent gynaecologists, and the binary responses of
the reference standard. The area under the receiver operating characteristic (AUROC) curve and 95% CI
was estimated for each test. Differences between the AUROC estimates of each of the four diagnoses
(pre and post laparoscopy by treating gynaecologist, and pre and post MRI by independent gynaecologist)
were then calculated using a non-parametric approach for correlated data and are presented along with
the 95% CIs. The same analysis was done to compare the responses after the MRI data were revealed to
the EIP.
Cost-effectiveness evaluation
The cost-effectiveness for a range of scenarios for MRI and laparoscopy using different sensitivity and
specificity values, as well as do-nothing (no MRI or laparoscopy) scenarios, was examined for women with
undiagnosed CPP.
A decision-analytic model with a 6-month time horizon was developed in consultation with the clinical
and methodological team. Two pathways for laparoscopy and MRI were constructed, with the cut-off
value on the receiver operating characteristic (ROC) curve used to inform the sensitivity and specificity of
each test being treated as a decision variable. Data collected in the MEDAL study to inform the prevalence,
quality-adjusted life-year (QALY) and test-accuracy data were used to parameterise the economic model.
Cost data were obtained from standard NHS sources.
A cost–utility analysis was undertaken based on the primary outcome of cost per QALY. The secondary
outcomes of the cost per patient correctly diagnosed and the cost per patient appropriately treated were
also considered as part of the wider cost-effectiveness analyses. The perspective of the analysis was the
health-care provider perspective (the UK NHS) in a secondary care (hospital) setting. Given the 6-month
time horizon, no discounting was applied. The results in this study are described using the incremental
cost-effectiveness ratio (ICER). A range of one-way sensitivity analyses were undertaken to gain further
insights into the impact of reasonable changes on key parameters in the model. A probabilistic sensitivity
analysis was also conducted.
Results
Main findings of the test-accuracy study
The diagnostic study demonstrated that, compared with the reference standard diagnosis verified with
laparoscopy, MRI had high specificity but poor sensitivity for observing deep-infiltrating endometriosis (3%),
endometrioma (33%), adhesions (19%) and ovarian cysts (20%). Sensitivity was higher for detecting these
conditions as a cause of pelvic pain, as categorised by the EIP, but not high enough to be useful. MRI
correctly identified 56% (95% CI 48% to 64%) of women judged to have idiopathic CPP, but missed
46% (95% CI 37% to 55%) of women considered to have a gynaecological structural cause of CPP.
Magnetic resonance imaging added significant value in the care pathway for determining the cause of
pain over and above the information gained by history, gynaecological examination and pelvic ultrasound
(before performing diagnostic laparoscopy) in identifying deep-infiltrating endometriosis (p = 0.006) and
endometrioma (p = 0.02), but not for other gynaecological structural causes or for identifying idiopathic
CPP (p = 0.08).
Laparoscopy was significantly more accurate than MRI in diagnosing idiopathic CPP (p < 0.0001),
superficial peritoneal endometriosis (p < 0.0001), deep-infiltrating endometriosis (p < 0.0001), and
endometrioma of the ovary (p = 0.02) as the cause of pelvic pain. The accuracy of laparoscopy appeared
able to rule in these diagnoses. Laparoscopy was not able to make accurate diagnoses that adhesions
were the cause of pelvic pain, nor to diagnose adenomyosis.
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Using MRI to identify women who require therapeutic laparoscopy would lead to 369 women in a cohort
of 1000 women receiving laparoscopy unnecessarily, and 136 women who required laparoscopy not
receiving it. A strategy of all women receiving laparoscopy would lead to 557 women who do not need
laparoscopic treatment receiving it.
Main findings of the economic evaluation
Feeding these diagnostic performance data into a decision-analytic model to inform cost-effectiveness
demonstrated that, for the majority of cut-off values used in the analysis, laparoscopy was found to be more
effective, in terms of QALYs gained, than MRI. Laparoscopy was found to be increasingly cost-effective for
longer time horizons. Extensive sensitivity analysis shows that, compared with laparoscopy, MRI is never a
cost-effective option.
Conclusions
With respect to specific gynaecological conditions, MRI was accurate for endometrioma, adhesions, ovarian
cysts and fibroids when compared with observations at laparoscopy. When compared with assignment of a
cause for CPP symptoms by an expert panel, MRI was accurate for endometrioma, adhesions and fibroids.
For determining the cause of pain, MRI added value in the care pathway over and above the information
gained by history, gynaecological examination and pelvic ultrasound (before performing diagnostic
laparoscopy) for the target conditions of deep-infiltrating endometriosis and endometrioma. The evaluation
of non-gynaecological conditions suffered from a lack of agreement over verification of diagnosis by an
expert panel, and this limits the useful interpretation of the data.
As a result of the extensive assumptions that were required to complete the economic analysis, the
findings of the economic evaluation are insufficient on their own to inform practice. This study has shown
that diagnostic laparoscopy is more cost-effective than MRI, although the importance of extending the
time horizon and the cut-off point for the sensitivity and specificity of the tests has been demonstrated.
Strengths and limitations
Construction of an appropriate study designed to produce valid, reliable and generalisable results to guide
decision-making proved challenging from the outset. The challenges included, among others, the variation
in gynaecological practice, the multiplicity of target conditions with respect to the cause of CPP, the
incongruence between observed conditions and attribution of the cause to CPP symptoms, the lack of
consensus on radiology standards and the reporting of pelvic MRI for benign gynaecological conditions,
the need to blind MRI results to avoid bias in the assessment of their value and the lack of objective
reference standards for the various target conditions.
There is little evidence as to how diagnostic consensus panels should be operationalised. We piloted and
then used a standardised approach to minimise variation in delineation of the reference standard, involving
independent gynaecologists who provided the reference diagnosis for each case presented based on the
consensus achieved through reviewing the structured summaries or full accounts of all the data collected.
Understanding the difference between the presence of a condition and a target condition being the cause of
pain proved to be the main challenge. During the course of the panel assessments, we undertook formal
repeatability testing and found that the inter-rater agreement for assignment of gynaecological conditions as
causes of CPP was good or very good, though it was poor or moderate for non-gynaecological conditions.
The strength of this model-based economic analysis is that it has utilised contemporary data from the
MEDAL study and considered the cut-off point on the ROC curve to inform the optimum sensitivity and
specificity for each test. However, it was limited to a 6-month time horizon for the data collection and
does not capture the full long-term effects of successful testing and treatment for women with CPP.
This means that the full patient benefit of laparoscopy and MRI has perhaps not been considered.
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Implications for health care
Magnetic resonance imaging was dominated by laparoscopy in differential diagnosis of women presenting to
gynaecology clinics with CPP. It did not add value to information, already gained from history, examination
and ultrasound, about idiopathic CPP and various gynaecological conditions before considering a laparoscopy.
To realise the little value that MRI did show for a few conditions, such as endometrioma and deep-infiltrating
endometriosis, a value judgement about cost-effectiveness would have to be made, as the diagnostic gain
from performing a MRI scan comes tagged with additional costs.
Recommendations for further research
The evaluation of tests for differential diagnosis in care pathways targeting various conditions for
treatment requires methodological development (e.g. in areas of consensus science with respect to panel
member numbers, sample size of cases for reliability). For CPP, the development of diagnostic prediction
models incorporating biomarkers into baseline data may improve the use of diagnostic laparoscopy, but
research will first be required to determine objective diagnostic criteria for the various target conditions
and valid biomarkers for endometriosis.
Trial registration
This trial is registered as ISRCTN13028601.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Definition and prevalence of chronic pelvic pain
Chronic pelvic pain (CPP) may be defined as pain in the pelvic and lower abdominal region that lasts for
6 months or longer.1 Idiopathic CPP is defined as CPP with an uncertain or unknown structural cause, that is,
CPP that is unrelated to gynaecological organs, after the exclusion of other recognisable gynaecological
pathology.2 Symptoms include dysmenorrhoea (painful periods), dyspareunia (pain during sexual intercourse),
dyschesia (painful bowel motions), dysuria (painful micturition) and constant or intermittent pelvic pain,
which may or may not be related to the menstrual cycle.3
In primary care, the annual prevalence of CPP is 38 out of 1000 in women aged 15–73 years,4 a rate
comparable with that of asthma (37/1000) and chronic back pain (41/1000).5,6 Unusually, no effective
management policy exists for CPP. Only 20–25% of women respond to conservative treatment.7 CPP
remains the single most common indication for referral to a gynaecology clinic, accounting for 20% of all
outpatient appointments.8
Personal and societal costs of chronic pelvic pain
Chronic pelvic pain can have a substantial negative effect on a woman’s quality of life (QoL). Women with
CPP tend to report reduced general physical health scores than those without pain.9,10 Women with CPP
describe loss, social isolation and effects on relationships. They have a high incidence of comorbidity, sleep
disturbance and fatigue.3 They tend to cope outside the health system and usually do not see a health-care
provider.8 Pain affects daily activities; around 18% of employed women in the UK take at least 1 day off
work each year because of such pain.9 The annual direct cost of health care for women with CPP was
estimated to be £158M, with a further £24M in indirect costs, in 1992.11 More recent data for endometriosis
estimated that the total annual societal burden of endometriosis-related symptoms was approximately
£8.2B, with 1.5 million women affected.12
Pathogenesis of chronic pelvic pain
The pathogenesis of CPP is poorly understood. CPP may be a symptom of a single or multiple coexisting
structural pathologies. The source of the pain can be either visceral (including the reproductive, urinary and
gastrointestinal tracts) or somatic (including the pelvic bones, ligaments, muscles and fascia). The most
recent taxonomy of pain from the International Society for the Study of Pain (ISSP) lists conditions such as
endometriosis, fibroids, adenomyosis, cystic ovaries and pelvic inflammatory disease (PID) as pathological
causes of CPP.13 Adhesions, frequently associated with endometriosis and pelvic congestion syndrome,
are not defined within the ISSP taxonomy and, indeed, the relationship between CPP and pelvic vein
insufficiency is controversial.14 The severity of pain may not be related to the severity of the underlying
pathology, as illustrated by endometriosis, when the stage of disease is poorly correlated with reported
pain.15 Pelvic pain may not be gynaecological in origin, however. Musculoskeletal dysfunction can include
muscle laxity, manifesting as pelvic organ prolapse, muscle spasms (which can potentially lead to nerve
entrapment) and trigger points (hyperirritable regions within skeletal muscle). Finally, pelvic pain may
have origins in the bowel or the bladder. Irrespective of the underlying cause, women with CPP are more
likely to have structural and functional changes to the central nervous system, and an increased risk of
psychological distress and dysfunctional stress responses, than pain-free control women.16
A significant proportion of women with CPP appear to have no obvious underlying pathology identified
during laparoscopy.17 Differences in the clinical thresholds for performing laparoscopy may vary over time
or location, but data from the UK-based LUNA (Laparoscopic Uterosacral Nerve Ablation) trial17 showed
that clinicians did not identify any condition at laparoscopy in 54% of participants. In these cases, the CPP
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may have had an unknown cause that was not related to gynaecological organs and could be referred to
as ‘idiopathic’. The ISSP and European Association of Urology (EAU) define a subgroup of CPP, in which no
obvious disease is found, to be CPP syndrome.13,18 Endometriosis-associated pain, vulval pain, bladder pain,
primary dysmenorrhea and CPP with cyclical exacerbations are differentiated as subtypes of CPP syndromes
by the ISSP. The EAU notes that, when pain is localised to a single organ, some specialists designate the
pain accordingly, for example bladder pain syndrome, but when pain is localised to more than one site,
the term ‘CPP syndrome’ should be used. Categorisation of the symptoms of idiopathic CPP syndrome into
functional and psychological categories may then be appropriate. In a proportion of women, there may be
a psychosomatic component, and psychological symptoms may be both causative and associative.
For this study, we used a working definition of idiopathic CPP with an uncertain or unknown structural
cause after the exclusion of any other recognisable gynaecological pathology. This was derived by a nominal
group method using an expert independent panel (EIP). A diagnosis of idiopathic CPP was arrived at once
all other organic causes of pain were excluded by various diagnostic technologies or empirical treatment.2
Variation in the presentation of chronic pelvic pain
Symptoms experienced in CPP are variable and non-specific, so establishing a differential diagnosis can be
hard. With this chronic condition, women present repeatedly over several years.19 It is possible in these
cases that a previously diagnosed condition (e.g. endometriosis) has recurred or a new condition has
developed (e.g. depression in a woman previously diagnosed with endometriosis). At present, there is wide
variation in clinical practice concerning the diagnosis and management of CPP.20 Women go from pillar to
post, seeing several health professionals before eventually having their underlying condition identified. This
wastes both the patient’s time and NHS resources. The diagnosis of endometriosis may be delayed by over
8 years after first presentation with CPP symptoms,19,21,22 potentially demoralising the patient and missing
the opportunity to improve their QoL and fertility through early effective treatment.
Diagnosis of the cause of chronic pelvic pain
A troublesome clinical issue is the lack of accurate tools to efficiently diagnose and direct cases of
women.23 The Royal College of Obstetricians and Gynaecologists (RCOG) guidelines on the management
of CPP provide a number of suggested initial investigations, including history, microbiological screening
and vaginal examination, all with weak evidence (levels B or C) for recommendations.20 If no cause of pain
is found, the first port of call is often to perform a diagnostic laparoscopy.
Clinical assessment and ultrasound
The order of tests in current practice can vary between clinicians and according to presentation, but the
RCOG’s clinical guidelines20 suggest that a clinical history is taken and a vaginal examination is performed.
When there is suspicion of PID or a potential need, screening for chlamydia and gonorrhoea in women
aged < 25 years may be performed. A transvaginal ultrasound may be performed,24 followed by a
laparoscopy under general anaesthetic.
Laparoscopy
Diagnostic laparoscopy is a surgical procedure that allows a clinician to view the contents of the abdomen or
pelvis to inform a diagnosis of CPP. A therapeutic laparoscopy is a surgical procedure used by a clinician to
treat various conditions that may cause CPP. Endometriosis, pelvic adhesions, chronic PID and ovarian cysts
are often observed via laparoscopy in women with CPP.8 In a cohort of 487 women recruited into a trial
of neuroablation for CPP, 54% of women had no identifiable pathology at laparoscopy, whereas 31% had
endometriosis, 5% had PID and 17% had adhesions.17 Approximately 11% had more than one finding.
Those women with moderate to significant pathology were excluded from this trial. This is in broad
agreement with other surveys.8
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The role of laparoscopy in the differential diagnosis of chronic pelvic pain
There is evidence to suggest that deep-infiltrating endometriosis, bladder pain syndrome/interstitial cystitis25
and irritable bowel syndrome26,27 are causally related to CPP, whereas, for adhesions, there is fair evidence.
The associations between severe endometriosis and pelvic pain, and between endometriosis in general and
infertility, are confirmed. However, there is little or no association between minimal endometriosis, pelvic
adhesions or dilated pelvic veins and pain.28 Debate remains over the relation between observed superficial
peritoneal endometriosis and the extent of the laparoscopic finding,29 or with the degree of reported pain.28
A combination of the non-invasive tests for the diagnosis of endometriosis can sometimes provide insufficient
or poor-quality evidence.30 However, of all conditions associated with CPP, many are not amenable to either
laparoscopic diagnosis or treatment. Of those conditions for which laparoscopy has a role, most are managed
by gynaecologists, and this probably explains the common use of laparoscopy for evaluating women with
CPP. Over 40% of laparoscopies are performed solely as a diagnostic test to identify the causes of CPP.31
The decision to perform a laparoscopy should be based on the history, physical examination and ultrasound
scans suggesting a visceral origin.
The accuracy of laparoscopy in the diagnosis of chronic pelvic pain
The value of laparoscopy as a diagnostic tool for CPP has been considered in several papers,8,31,32 including
a review of published reports of laparoscopically diagnosable conditions, in which an average of 61% of
women undergoing laparoscopy for CPP had an identifiable pathology, compared with pathology in 28%
of those without CPP.8 However, invisible (occult) endometriosis can be present in a seemingly normal
peritoneum.33 A ‘negative’ laparoscopy for some women may lead to them feeling disappointed that no
diagnosis has been made34 and disengage them from the care pathway.35
However, a visual diagnosis of endometriosis during laparoscopy has been demonstrated to be unreliable.
Only 54–67% of suspected endometriotic lesions are confirmed histologically, and 18% of women clinically
suspected to have endometriosis have no evidence of endometriosis in biopsy samples.36 A meta-analysis
found that a positive finding through the use of laparoscopy will not be verified by histology in half of the
cases (assuming a prevalence of 20%), although a negative laparoscopy is highly accurate for excluding
endometriosis.37 Other conditions identifiable through laparoscopy are listed in Table 1.
Magnetic resonance imaging in the diagnosis of chronic pelvic pain
Advances in imaging techniques suggest that magnetic resonance imaging (MRI) may be a useful non-
invasive tool for diagnosing some conditions that cause CPP, such as adenomyosis44 and deep-infiltrating
endometriosis.45 MRI has an established role in the diagnosis of adenomyosis and is currently the most
accurate available non-invasive test in use.46 The role of MRI in diagnosing small deposits of endometriosis20 is
less established. A Cochrane review reported that no imaging techniques met the criteria for a replacement or
triage test for detecting superficial pelvic endometriosis.30 Several factors contribute to this poor accuracy of
MRI: non-pigmented lesions will not be hyperintense on T1 scans, small focal lesions may have variable signal
intensity, plaque-like lesions are hard to delineate and adhesions cannot be directly identified, but are implied
when the normal anatomy is distorted. Other conditions, such as fibroids and congenital uterine anomalies,
may co-exist and are accurately diagnosed with MRI.47
Magnetic resonance imaging is currently not recommended in guidelines nor used in routine practice for
the investigation of CPP; the important question is whether or not a normal MRI scan has a high enough
negative predictive value to replace and avoid laparoscopy. In CPP women, MRI may potentially have an
important role in eliminating the need for surgery.
There are currently no agreed standardised protocols for MRI of the pelvis in the evaluation of pelvic pain.
Radiologists determine the protocol used based on the clinical information and the suspected pathology,
as well as personal preference and experience. Various bodies, such as the European Society of Urogenital
Radiology (ESUR), have recommended protocols for pelvic assessment for various conditions,48 but none
specifically addresses CPP.
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Treatment of chronic pelvic pain
As diagnoses emerge through careful history and examination and directed investigation, so may treatment
strategies. These should be tailored to the needs of individual women, whatever the cause. A multidisciplinary
approach is considered ideal for achieving this. Chronic symptoms need long-term management and a
multimodal approach.
Some clinicians prefer that a diagnostic and therapeutic investigation is performed as part of a single
procedure – sometimes referred to as ‘see-and-treat’ laparoscopy.49,50 For example, adhesiolysis may be
performed in what started as a diagnostic procedure.51 Depending on the severity and corresponding
patient consent, endometriosis may be treated at the time of diagnosis by either electrocoagulation, laser
vaporisation or excision.52 Endometrioma and benign ovarian cysts are usually excised.53 The type of
treatment offered may depend on the extent of the disease and surgical expertise. Surgical removal of
deep-infiltrating endometriosis is highly specialised and, in the UK, undertaken in accredited specialist
centres. Preoperative MRI scans can aid the planning of this complex surgery.
Other conditions observed at laparoscopy are not amenable to immediate laparoscopic treatment,
for example myomectomy for subserosal fibroids.54 Few surgeons attempt uterine-sparing surgery for
adenomyosis, as a result of it frequently being diffused throughout the myometrium.
A diagnostic laparoscopy may also provide the opportunity to undertake other investigations, such as a
cystoscopy, if symptoms are suggestive of bladder or intrauterine conditions. Some gynaecologists may
also use the cover of a general anaesthetic to perform investigations capable of being performed as an
outpatient procedure, such as hysteroscopy or insertion of a levonorgestrel-releasing intrauterine system.
TABLE 1 Summary of the evidence for accuracy of magnetic resonance imaging and laparoscopy in the
investigation of CPP
Target conditions Diagnostic criteria
Diagnosis by
MRI Laparoscopy
Endometriosis Visualisation of endometriotic
lesions with histological
confirmation of biopsies from
lesions37
Uncertain. MRI had a sensitivity of
85% and a specificity of 89%
for detecting biopsy-proven
endometriosis38
MRI had a sensitivity and a
specificity for diagnosis of
rectovaginal deep-infiltrating
endometriosis of 55% and 99%,
respectively. Sensitivity for other
locations was considerably higher,
for example, on uterosacral
ligaments it was 85%39
Negative laparoscopy was accurate
for excluding endometriosis
(pooled LR –0.06, 95% CI 0.01 to
0.47) compared with biopsy, but
positive findings were not as
accurate (pooled LR 4.30, 95% CI
2.45 to 7.55)37
Adhesions Visualisation, directly or by
absence of movement
between adjacent organs
Evidence from a single trial:
sensitivity of 88% and specificity
of 93%40
Gold standard
Chronic PID Laparoscopic visualisation or
histology from fimbrial mini
biopsy
Ultrasonography represents
preferable initial non-invasive
diagnostic method. MRI sensitive
for tubal, ovarian and pelvic
abscesses41
Can confirm tubo-ovarian
abscesses and the presence of
Fitz-Hugh–Curtis syndrome, but
may fail to detect early disease or
those with endosalpingitis only42,43
Adenomyosis Presence of diffuse
endometrial tissue in
myometrium at post-
hysterectomy biopsy
MRI had a pooled sensitivity of
77% and a specificity of 89%
against histological diagnosis44
Uncertain. May observe bulky
uterus
CI, confidence interval; LR, likelihood ratio; MRI, magnetic resonance imaging.
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Medical treatments are also options for CPP, irrespective of surgical intervention. The combined oral
contraceptive pill is used post laparoscopy for prevention of the recurrence of endometriosis, as are
long-acting reversible contraceptives.55–57 Gabapentin is used for women with no identifiable cause of pain,
although evidence for its efficacy is limited.58
Overview of the Magnetic resonance imaging for Establishing Diagnosis
Against Laparoscopy study
The MRI for Establishing Diagnosis Against Laparoscopy (MEDAL) study recruited women from 26 UK
hospitals (as listed in Appendix 1, Table 29). An outline of the test-accuracy study design is shown in
Figure 1. MRI was undertaken before laparoscopy, but the resulting report and images were not to be
provided to the gynaecologist, unless there was a critical finding, such as suspected malignancy. This
blinding was necessary in order not to distort clinical practice and avoid verification bias arising from
knowledge of this index test. A diagnostic laparoscopy was performed and, together with information
from the history, examination and ultrasound, produced a post-laparoscopy diagnosis (Figure 2).
Information was collected from those who were not eligible for the test-accuracy study. Follow-up
information was elicited directly from participants at 6 months.
An economic evaluation was performed to establish the cost-effectiveness of MRI as an alternative to
laparoscopy for the sensitivity and specificity values of the various target conditions.
Rationale for the Magnetic resonance imaging for Establishing Diagnosis
Against Laparoscopy study
There is a perception that diagnostic laparoscopy, an invasive, expensive and potentially risky procedure, is
used far too frequently in the NHS, as a significant proportion of women have no pathology identified.59
The procedure is associated with an approximate 3% risk of minor complications (e.g. nausea and vomiting,
shoulder-tip pain) and a 0.24% risk of unanticipated injury causing major complications (e.g. bowel
perforation), resulting in two-thirds of women requiring laparotomy.59–61 There is an estimated risk of death
of 3.3 to 8 per 100,000 women,59,61 and payments in medical negligence cases totalled £24.3M in one
survey published in 2000.62
Magnetic resonance imaging is easily accessible, less invasive and cheaper than surgery. In some circumstances,
MRI may add a diagnostic benefit over laparoscopy, such as in the cases of severe deep-infiltrating endometriosis
and adenomyosis. MRI may also be used to triage cases, so that therapeutic laparoscopy could be better
planned. The aim of the MEDAL study was to determine the proportion of women for whom MRI could remove
the need for a laparoscopy or, in other words, for whom MRI could be a replacement for laparoscopy.
For MRI to be used in routine clinical practice for the evaluation of CPP, imaging protocols and reporting
need to be standardised to allow homogeneous MRI performance between centres and to limit acquisition
and interobserver variability. Currently, there are no routinely used standardised reporting guidelines for
CPP in the UK.63 Guided by the MEDAL study, members of the study panel have proposed a template for
the standardised reporting of CPP.63
Following various treatment options, such as the oral contraceptive pill or hormone treatment, some women
will undergo laparoscopy resulting in 50% of women having a negative laparoscopy with no pathological
cause of pain identified.8 Although a negative laparoscopy may fail to identify the pathology, it may have a
reassuring effect on the patient. A laparoscopy may also have the potential to be a ‘see-and-treat’ laparoscopy
if superficial peritoneal endometriosis is observed; MRI would add no benefit in that case.
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Women with CPP in secondary care 
approached for consent to participate in 
the study 
• Standardised history
• Examination
• Transvaginal ultrasound data
• Laparoscopy considered
Pre index 
Management of working diagnosis and
management plan
Treating gynaecologist
(blind to MRI report)
Radiology
(blind to laparoscopy report)
Independent gynaecologist
(blind to laparoscopy report) Expert independent panel
(reference diagnosis)
Working diagnosis (pre MRI/laparoscopy)
Gynaecologist performs laparoscopy
and produces report
Laparoscopy report and baseline data –
based on post-laparoscopy diagnosis 
Treatment and/or other investigations
initiated as per clinical practice
Follow-up information
Summary MRI diagnosis
Independent radiologist
(review of MRI scan) 
Radiologist performs MRI and
produces report 
IRRC
Pre-index data and MRI report
reviewed independently
Independent diagnosis
Pre-index data and laparoscopy 
report and follow-up information
Stage 1 diagnosis
Pre-index data and laparoscopy 
report and follow-up information 
and MRI diagnosis
(summary or consensus)
Stage 2 diagnosis
Data
Possible data 
FIGURE 1 The MEDAL study flow chart. IRRC, Independent Radiology Review Committee.
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The choice of study design
Test-accuracy studies are designed to generate measures of accuracy by comparison of the index test with
a reference standard, a test that confirms or refutes the presence or absence of disease beyond reasonable
doubt. Classical test-accuracy studies require that the target condition is independently verified by the
reference test, which must provide a definitive diagnosis, be applicable in all cases and preferably be
performed alongside the index test. Complete verification of the presence or absence of a target condition
is essential to reduce bias and to maximise the statistical power of the study. By comparing the index test
with the reference standard, the result of the index test can be categorised as a true positive, a false
positive, a true negative or a false negative. Measures of index test accuracy, including sensitivity,
specificity, positive and negative likelihood ratios, and diagnostic odds ratios, can be computed.64
Verification of the reference standard is frequently dichotomised as disease present/disease absent. In the
MEDAL study, we aimed to determine the accuracy of MRI in the differential diagnosis of the causes of CPP.
MRI scan needs to be reported to gynaecologist
• Ineligible
MRI scan not done or unblinded
• Patient now ineligible
Laparoscopy not done
• Patient now ineligible
Patient declines
• Ineligible
Ineligible
• Empirical medical treatment
• Referral to other services
• Patient postal questionnaire,
   comparable with baseline 
• Clinical/menstrual/obstetric history
• Patient questionnaires
• Clinical examination
• Transvaginal ultrasound 
   (some centres)
• MRI scan report
• Laparoscopy report
• Brief clinical history
• Transabdominal ultrasound scan 
   (some centres)
Follow-up information 
MRI scan performed
Gynaecology clinic
Laparoscopy performed (possible 
hysteroscopy, cystoscopy or biopsy)
GP referral to hospital
gynaecology clinic
Consent to participate in the 
MEDAL study
Requires MRI scan?
Working diagnosis report
Requires laparoscopy?
FIGURE 2 Patient pathway and data points through the MEDAL study. GP, general practitioner.
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There is a range of potential target conditions and, correspondingly, of reference diagnoses. MRI will visualise
the various conditions with different degrees of accuracy (Table 2). To determine the sensitivity of MRI for
each pathology would require a large number of participants, to accommodate the low prevalence of some
conditions. Furthermore, some pathologies are not independent of each other and could frequently be
concurrently observed; for example, endometriosis can give rise to adhesions from fibrotic tissue. Therefore,
the principal research question is how frequently does a MRI scan correctly predict the reference diagnosis,
thereby removing the need for a laparoscopy or, conversely, what diagnoses cannot be accurately ruled out
by a MRI scan and require laparoscopic investigation?
In the context of the MEDAL study, there were a number of target conditions to be considered, not all
of which had a perfect reference standard of identification against which to make a differential diagnosis.
There was a risk of partial or differential verification of the underlying causes, with their inherent biases.
TABLE 2 Radiological features identified on a pelvic MRI scan and the diagnostic criteria used
Radiological feature
Criteria used in analysis to indicate the
presence of a target condition Reference or justification
Anatomy of uterus, ovaries, adnexal
structure, bladder and bowel
Not used for analysis
Uterine size, appearance, JZ thickness,
adjacent myometrial thickness,
endometrial thickness
Adenomyosis is diagnosed in two ways:
1. If JZ is > 50% of adjacent myometrium
thickness (including JZ)
2. Thickness of JZ is > 13mm, in either the
anterior or the posterior wall or fundus
Presence of fibroids, location, number
and maximum size
Presence of fibroids reported, irrespective of
location, number or size
Fibroids are seen on the
MRI scan
Ovarian size, ovarian cysts, and,
if present, their size and signal
intensity
Endometrioma of the ovary is diagnosed if the
ovary had a cystic area or deposit with:
l high or intermediate signal intensity on T1, T2
and T1-FS images
l only a high signal intensity on T1, T2 and
T1-FS images
l [Cysts (other than follicles)= present, T2= high
and T1, T1-FS= low or intermediate]
Presence and location of other masses l Diagnosis of deep-infiltrating endometriosis if
masses or thickening are seen in the bowel or
bladder; and
l masses have a high or intermediate signal
intensity on T1 and T1-FS images
l masses have a high signal intensity on T1 and
T1-FS images
Bazot et al.,39 Bazot et al.65
and Chamié et al.66
Presence of free or loculated fluid Diagnosis of PID if either free fluid or tubal masses
are seen, with low or intermediate signal intensity
on T1, T2 and T1-FS images
Adhesions Diagnosis of adhesions if reported as:
l clearly seen
l clearly seen or suspected
Bladder status, including wall
thickness if abnormal
Not used for analysis
Presence of small bowel in pelvis,
location and description
Not used for analysis
Other observations; for example,
lumbar spine abnormalities
Not used for analysis
FS, fast spin; JZ, junctional zone.
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There are several proposed study designs that overcome the problems of an imperfect reference diagnosis.67
In the absence of a single ‘gold standard’ test, the results of several imperfect tests or observations can be
combined to create a composite reference standard. These can be combined according to a predefined
algorithm or a consensus diagnosis obtained from considering all the information.
We employed a panel (consensus) diagnosis in which a group of experts determined the presence or
absence of the target condition based on several sources of information captured along the patient
pathway. This was an acceptable way of addressing the problem of achieving a diagnosis from multiple
sources of information and of subjective assessment of that information, as a diagnosis is achieved by
consensus.68 A final diagnosis can be obtained for all women and the panel method reflects the clinical
reality, in which several items of information are synthesised by the clinician. The results of this methodology
can be viewed as being generalisable to clinical practice.
To establish whether or not MRI can replace laparoscopy, a paired design was employed, in which both tests
were compared with the reference standard. As sensitivity and specificity can vary across subgroups, the two
tests and the reference standard are best performed in the same population.68 It is feasible to perform MRI
and laparoscopy in women with CPP and, although MRI does not interfere with laparoscopy, the paired
design is preferable to a randomised trial.69 As MRI would precede laparoscopy, it can also be viewed as a
triage test, directing only women with a specific condition towards a laparoscopic confirmation or operative
laparoscopic procedure. A fully paired study design is also appropriate for this type of diagnostic situation.
The certainty with which gynaecologists have made their diagnoses will be measured and compared as a
secondary measure of diagnostic efficacy. In order to be clinically effective, tests should contribute to the
diagnostician’s decision-making,70 for example, by changing a differential diagnosis, strengthening an
existing hypothesis or simply reassuring the clinician. Although accuracy is the chief concern, the extent to
which clinicians make use of test results also relies on their confidence that the test has contributed
usefully to a diagnosis. The MEDAL study therefore evaluated the diagnostic impact of MRI and of
laparoscopy by conducting a:
1. before-and-after comparison of diagnostic certainty for having diagnosed the cause of CPP
2. before-and-after comparison of diagnostic certainty for the leading diagnosis
3. before-and-after comparison of the number of differential diagnoses considered per patient
4. retrospective survey of the test’s perceived usefulness.
On the basis of clinical history, examination and ultrasound findings only, treating gynaecologists were asked
to state whether or not a pathological cause for CPP was identified, and to express their certainty regarding
this decision. They were also asked to list their differential diagnoses, to state whether each was thought to be
a cause of CPP and to express their certainty regarding these opinions. After the laparoscopy was performed,
clinicians were asked for a revised differential diagnosis and associated certainty using identical questions.
A comparison between pre- and post-laparoscopy diagnostic certainty was made, primarily to determine the
utility of laparoscopy for identifying a pathological cause of CPP, and secondarily to compare changes in the
certainty surrounding the leading differential diagnosis. The number of differential diagnoses considered
before laparoscopy was also compared directly with the number considered after the test results were known.
An identical process was followed with independent non-treating gynaecologists (who were blind to the
laparoscopic findings) who used MRI to arrive at a diagnosis. Pre-MRI diagnoses and associated certainty
based on the same clinical history, examination and ultrasound findings were compared with post-MRI
revised diagnoses and certainties. Independent gynaecologists were also asked whether or not they
believed that the patient required a laparoscopy.
The gynaecologist’s subjective assessment of the usefulness of MRI or laparoscopy was evaluated after
disclosure of the relevant test results, by asking clinicians to select one of four statements that best
reflected their perception of the contribution of the test to each case. These statements were initially
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drafted with reference to those used in published before-and-after diagnostic confidence studies,71–73 and
modified for their relevance to a CPP diagnosis following consultation with eight practising gynaecologists.
Aim and objectives
Aim
The aim was to assess if MRI could add value to the decision to perform a laparoscopy in women
presenting with CPP. In doing so, we wanted to determine the number of women for whom MRI is
sufficiently accurate to avoid the need for a laparoscopy in the investigation of CPP, following evaluation
of the presenting characteristics with a detailed history, clinical examination and ultrasound.
Objectives
l To estimate the accuracy of post-MRI diagnoses with respect to:
¢ the absence of any observed condition or cause, that is, idiopathic CPP
¢ the main gynaecological conditions or causes of CPP as target conditions, using post-laparoscopy
diagnoses and EIP consensus (with and without incorporating MRI findings) as reference standards.
l To determine the added value of MRI in a care pathway involving baseline history, clinical examination
and ultrasound before performing laparoscopy.
l To quantify the impact that a pre-laparoscopy MRI scan can have on decision-making with respect to
triaging for therapeutic laparoscopy.
l To determine the cost-effectiveness of MRI compared with laparoscopy.
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
Chapter 2 Methods
Introduction
We conducted a test-accuracy study in a prospective cohort of women with CPP symptoms, subjected
them to thorough investigations, including our index tests (MRI scan and laparoscopy), and sought expert
panel consensus to establish a reference diagnosis. We performed a comparative test-accuracy study with
panel consensus for determining the reference standard.
Oversight
The study was conducted in accordance with the protocol, which received a favourable ethics opinion
from East Midlands (Nottingham 1) Research Ethics Committee (reference number 11/EM/0281). NHS trust
research governance approval was obtained from 26 recruiting hospitals in the UK. The study sponsor was
the Queen Mary University of London. Independent oversight for the MEDAL study was requested by the
funding body; however, how this oversight should be arranged or what it should entail were unclear,
as the study was not considered to be distinct from that of randomised controlled trials. For the MEDAL
study, the Data Monitoring Committee was defined as a subgroup of the Study Steering Committee (SSC).
All members were independent of the MEDAL study management group. The chairperson of the SSC
(along with the lay member) was not included in the Data Monitoring Committee.
Study oversight was provided by an independent steering committee and an independent data monitoring
committee (see Acknowledgements for membership).
Study participants and setting
Any woman aged ≥ 16 years, who had been referred to a gynaecologist with CPP of at least 6 months’
duration, was potentially eligible. Women were assessed by a gynaecologist, which involved a standardised
assessment and a clinical examination. If clinically indicated, women were referred for an ultrasound scan.
If a laparoscopy was indicated and the patient wished to proceed with the laparoscopy, and was prepared
to have a MRI scan, eligibility to participate in the study was confirmed. Women were excluded if they had
had a hysterectomy, were pregnant or were unable to give written informed consent, or if they definitely had
a clinical indication for a MRI scan, based on examination, history or ultrasound. Women were also excluded
if they had an identifiable cause of CPP for which treatment could be initiated without a laparoscopy. Eligible
women who provided written informed consent were committed to the study by telephone registration
service at Birmingham Clinical Trials Unit (University of Birmingham, Birmingham, UK).
Pre-index tests
History and patient-completed questionnaires
A structured assessment template for use by all gynaecologists was provided, which first collected data
from the participant and then allowed the clinician to create a clinical record. The assessment incorporated
(1) demographic details; (2) menstrual, contraceptive and obstetric history; (3) tobacco and alcohol use;
and (4) previous investigations and treatments for pelvic pain. Visual analogue scales were used to elicit
scores (from 0 to 10) for pain symptoms of (1) dysmenorrhea (including pain occurring pre menses, during
menstruation, post menses and mid-cycle); (2) dyspareunia (at the point of penetration, deep pain, burning
pain, post-coital pain); (3) dysuria (full bladder, micturition); (4) muscle/joint pain in the pelvis; and
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(5) backache and migraine. A body map to illustrate the location of pain was also provided. The assessment
also included standardised patient-completed questionnaires, previously validated in either women with
pelvic pain or other clinical symptom groups. The domains captured by the questionnaire components of
the assessment were:
l neuropathic pain symptoms, measured using the short-form McGill Pain Questionnaire74
l bowel symptoms, measured using the Rome III diagnostic criteria75
l urinary problems, measured using the Pelvic Pain and Urgency/Frequency (PUF) Patient Symptom Scale76
l sexual activity, measured using the Sexual Activity Questionnaire77
l personality characteristic, measured using the Big Five Inventory scale78
l psychological coping strategies, measured using the Pain Catastrophizing Scale79
l endometriosis-related pain, measured using the Short Form Endometriosis Health Profile Questionnaire
(EHP-5)80
l risk of depression, measured using the Patient Health Questionnaire depression module (PHQ-2)81
l sexual and physical abuse history, measured using the Sexual and Physical Abuse History
questionnaire82
l QoL and well-being, measured using the EuroQol-5 Dimensions, three-level version (EQ-5D-3L)
instrument and the Investigating Choice Experiments CAPability (ICECAP)-A measure.83,84
Clinical examination and ultrasound
Each woman underwent a clinical examination by the recruiting gynaecologist. A data collection form helped to
direct the examination, which aimed to describe the location of any abdominal tenderness, and any tenderness,
erythema, discharge or lesions on the external genitalia. A bimanual examination aimed to identify vaginismus,
bladder wall or uterosacral ligament tenderness, cervical excitation, uterine size, position, contour, consistency
and mobility, ovarian tenderness, mobility and presence of masses. A speculum examination of the vagina was
used to identify prolapse, vaginal atrophy, polyps and cervicitis, and also allowed swabs to be taken if indicated
and if the woman consented. A urine sample was provided to perform a dipstick test to detect urinary tract
infection.
The intention was for all women to have a detailed ultrasound scan, in accordance with the study protocol,
scanning by both the transabdominal route on a full bladder and then the transvaginal approach on an
empty bladder. However, in some centres, the ultrasound was scheduled with a sonographer prior to the
first appointment with the gynaecologist. In these cases, it was not possible to repeat the ultrasound, and
an incomplete data set for the study was extracted from the report. The intention was to describe the
uterine size by both approaches, and also to examine the uterine position, myometrial appearance and
endometrial width, as well as ovarian size, location and presence of ovarian cysts and, finally, bladder wall
thickness, all by transvaginal ultrasound. Further information sought included the presence of free or
loculated fluid and organ- or site-specific tenderness or restricted mobility.
Index tests
Magnetic resonance imaging scan
Women were asked to fast for 2–4 hours prior to the scan and not to empty their bladder immediately
prior to the scan. Antiperistaltic agents were contraindicated, but antispasmodic drugs were acceptable.
The MRI standard protocol comprised T1 and T2 axial, T2 sagittal, T2 coronal and T1-fast-spin (FS) axial,
sagittal and coronal sequences, using standardised anatomical landmarks, slice thicknesses and field of
view. If unexpected abnormalities were detected, additional sequences, potentially using the contrast
media gadolinium, could be added to the scanning protocol to enable further clarification and assessment.
To ensure blinding of assessments, a MRI scan was performed before diagnostic laparoscopy, and treating
gynaecologists and investigators were kept blind to the MRI reports and images. To identify radiological
METHODS
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parameters for inclusion in the MRI report, a two-generational Delphi survey with an expert panel of
28 radiologists specialising in gynaecological MRI from across the UK was undertaken.63 The MRI report
collected data described in Table 2.
The radiologists’ assessments of the quality of the scan were captured, and they were asked to summarise
the observations and provide a radiological diagnosis in free-text form.
The MRI scan was also independently reported by a second radiologist who was blinded to the initial
MRI report. This would be a radiologist involved in reviewing scans for the study, but based at a different
site from the initial reporting radiologist. Where the local and independent radiologists agreed on the
summary diagnosis, the findings were accepted as a consensus and provided the ‘post-MRI diagnosis’ data
for analysis. Lack of agreement between local and independent radiologists prompted a review by the
Independent Radiology Review Committee (IRRC), made up of three experienced radiologists who were
not involved in imaging participants in the study. The IRRC agreed a consensus MRI report. The finalised
report was provided to the independent gynaecologist for determining the post-MRI diagnosis, and to the
EIP for the second stage in the reference diagnosis.
The diagnostic criteria used for the analysis of the accuracy of MRI are given in Table 2. These were defined
by the lead radiological investigator and confirmed by a second radiologist otherwise not involved in the
study. There were potential variations in diagnosis, for example in relation to whether an intermediate signal
from a T1 and T1-FS image of a bowel mass was indicative of deep-infiltrating endometriosis; therefore, the
different diagnostic criteria were considered in alternative or sensitivity analyses.
The MRI reports were not provided to the gynaecologist unless unexpected significant findings were
identified by the local reporting radiologist. We prespecified the circumstances in which this may happen,
such as identification of an unexpected cancer, abscess or non-gynaecological abnormality requiring
immediate attention. In the case of unblinding, the participant was excluded from the diagnostic accuracy
study and managed appropriately.
Laparoscopy
The diagnostic laparoscopy was performed under general anaesthetic in accordance with the gynaecologist’s
standard practice. After a pneumoperitonium was established, a laparoscope was introduced to visualise
the abdominal and pelvic structures, and any pathology. Laparoscopy was performed by an experienced
gynaecologist who was capable of identifying all potential target conditions. Surgical findings were reported
using a standardised proforma, which collected the information described in Table 3.
When clinically indicated, additional procedures were performed at the time of surgery. Information was
collected on procedures, including ablation or excision of superficial endometriosis, ovarian cystectomy,
adhesiolysis, hysteroscopy (noting the presence of fibroids or the insertion of the levonorgestrel-releasing
intrauterine system), endometrial biopsies and histological confirmation of pathology and cystoscopy. If
bladder biopsies were collected, the histological confirmation of pathology was recorded.
Follow-up
Some of the target conditions may respond well to treatment; therefore, information was collected at
6 months following laparoscopy, using a postal questionnaire. The questionnaire contained all of the
elements of the initial patient questionnaire, including the visual analogue scales, validated questionnaires
and questions regarding further tests and treatments, but omitted the demographic and history questions,
as the answers to these questions would not have changed. Women were sent reminders if they failed to
respond to the initial questionnaire. The information gained from follow-up was considered by the EIP
when assigning the reference standard.
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Assigning the cause of pain
At several stages in the study path for each patient, the treating gynaecologist and the independent
gynaecologist reviewed the diagnostic evidence available. To establish a possible diagnosis for each
target condition (including idiopathic CPP), they indicated their level of certainty that the condition was
causing the pelvic pain on a numerical rating scale, ranking from 10 being certain (expressed as a 99 in
100 chance), through 5 being a fairly good possibility (a 5 in 10 chance) to 0, considered to be no chance
or less than a 1 in 100 chance.
The first condition was the absence of structural cause, defined as idiopathic or unknown. There then followed
seven structural gynaecological causes (superficial peritoneal endometriosis, deep-infiltrating endometriosis,
endometrioma of the ovary, adhesions, ovarian cysts, adenomyosis, fibroids), together with the option to specify
another gynaecological cause. The non-gynaecological causes offered were psychological or psychosexual,
gastrointestinal, urinary, musculoskeletal, neurological or another pathological cause, with the requirement
to specify the diagnosis further. Definitions for idiopathic CPP, superficial peritoneal and deep-infiltrating
endometriosis, adhesions and pelvic congestion syndrome were provided.
Determining the role of magnetic resonance imaging by
independent assessment
The treating gynaecologists were kept blind to the MRI scan report so that they could make an unbiased
assessment of the laparoscopic findings. If MRI was found to be useful in the MEDAL study, an MRI scan
would precede laparoscopy in the investigative pathway in the future. In order to model the impact of using
the MRI scan report, an independent gynaecologist reviewed each case. This gynaecologist was randomly
selected from another hospital recruiting to the MEDAL study, so was familiar with the study aims, processes
and data collection. The independent gynaecologist was provided with all the data collection forms for the
pre-index tests and clinical history, together with the laparoscopy report. The information was anonymised.
The independent gynaecologists were asked to complete the certainty scales for each condition, which
TABLE 3 Laparoscopic features identified via laparoscopy and criteria used
Laparoscopic feature
Criteria used in analysis to define the observation of the target
condition
Presence, location and severity of endometriosis Presence of endometriosis in any location, categorised as either
superficial or deep. Biopsies may have been taken for histological
confirmation, but the results were not considered for the criteria.
AFS grading was used85
Presence, location and appearance (filmy,
dense/vascular or an absent plane) of adhesions
Presence of adhesions in any location, irrespective of appearance
Presence of adenomyosis Presence of adenomyosis observed. It is acknowledged that
adenomyosis cannot be directly observed, but other features might
be suggestive
Presence, location, type (simple, dermoid,
cancerous, other) and size of ovarian cysts
Presence of any ovarian cysts, regardless of type
Presence, location and maximum size of fibroids Presence of any fibroids, regardless of location. It is acknowledged that
submucosal and small intramural fibroids cannot be directly observed,
but other features may be suggestive or they may have been observed
by hysteroscopy
Presence of PID Presence of features indicative of PID
Pelvic congestion syndrome Observation of dilated pelvic veins
AFS, American Fertility Society.
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constituted the pre-MRI independent diagnosis and should be highly correlated with the recruiting
gynaecologists’ diagnoses post laparoscopy, being derived from the same information. The independent
gynaecologists were then asked to read the MRI scan report and repeat the process, completing the certainty
scales. There were three extra hypothetical questions at this second post-MRI stage: if the gynaecologist was
treating that particular patient, would they have scheduled a laparoscopy (having reviewed the MRI scan
report), if they would have scheduled a therapeutic laparoscopy and, if so, would they anticipate that the
diagnostic and therapeutic elements would be performed as part of a single procedure?
Reference standard
The analysis considers two sets of reference standard. The first identified was to assess the accuracy of the
MRI scan for observing a condition, and the second was to assess the accuracy of the MRI scan for identifying
the condition(s) causing pelvic pain. The first set used findings from laparoscopy for the reference standard,
and the second used consensus from an EIP. It was expected that not all women who were observed to have
each condition would have it categorised as being the source of pelvic pain.
Piloting the expert independent panel
There is little evidence on how panels should be convened or how information should be presented.
Given the amount of information to be considered by the panel and the associated review time, the study
management group, in conjunction with the EIP chairperson, considered the use of a summary report.
To ensure that the diagnosis based on the summary report was the same as the diagnosis based on all of
the data collection forms (initial patient assessment, including patient questionnaire, clinical examination,
ultrasound, post-laparoscopy report and, finally, the MRI scan report), a pilot EIP panel was convened to pilot
and review the process. The pilot EIP panel consisted of three clinicians not involved in the study recruitment.
Ten cases were presented to the three members. For the first five cases, two of the three members used
the summary report and the third member used the data forms. For the last five cases, two members,
who had previously used the summary report, used the data collection forms. For each case, the members
defined a single or multiple diagnosis. Results from the meeting indicated that the summary report and
data collection forms allowed the members to produce the same diagnosis. Data collection forms were
preferred, or used in conjunction with the summary report, when cases were considered to be complex
(e.g. when a patient had multiple conditions and various confounding factors).
To elicit a diagnosis, a form with a list of the target conditions was provided. This was comparable to the
form used by the treating and independent gynaecologist, except that the certainty scale was not used and
simple yes/no answers were allowed. During the pilot EIP meeting, members were allowed to record multiple
causes. This was considered unsatisfactory as a reference standard, as they would complicate accuracy
assessments, so the initial guidance regarding the first eight cases presented to the main EIP members
was to diagnose what they believed to be the single main cause of pain. The process was performed in two
stages: once with all of the data, except those from the MRI report, and then a second time, including the
data from the MRI report. The first-stage diagnosis avoided incorporation bias from knowledge of the MRI
scan results, whereas the second-stage diagnosis provided information to determine the added value of the
MRI scan. Two further yes/no questions were posed to the panel: (1) does the laparoscopy add anything
to your diagnosis that was not available from other investigations and (2) could this laparoscopy have a
therapeutic purpose?
Feedback from these eight cases suggested that, in some instances, it was necessary to select more than
one condition, given that two or more conditions could equally be the cause of pain. The criteria and
guidance were changed so that EIP members could select any clinically appropriate conditions they
believed to be the cause of pain, provided that they were at least 50% certain. The diagnosis form still
allowed only yes/no answers, but multiple reasons could be given. The first eight cases were reviewed
again at a later meeting using the revised criteria.
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Expert panel membership and meeting format
The panel membership consisted of 15 consultant gynaecologists who were not involved in the study
recruitment. Each face-to-face meeting was made up of three members who provided the reference
diagnosis for each case presented based on the summary report of the data, with the individual data
forms available if required.
The first-stage reference diagnosis was based on patient history and reported symptoms, clinical
examination, ultrasound, laparoscopy and follow-up. For the second-stage reference diagnosis, the MRI scan
report was provided. For both stages, each EIP member individually recorded the conditions that they were
more than 50% certain were the cause of pain, and addressed the two questions regarding the potential
gain from the laparoscopy, prior to a group discussion. The meeting chairperson documented the discussion
and how agreement was reached, and the final consensus diagnosis constituted the reference standard.
Sample size
A sample size of 250 women was chosen a priori to address the primary research question of determining
the proportion of women for whom MRI is sufficiently accurate to replace laparoscopy in the investigation of
CPP, following evaluation of the presenting characteristics. With this sample size, the study was anticipated
to have > 90% power (at p = 0.05) to detect a reduction of 10% in the number of laparoscopies needed
(i.e. from 100% down to 90%). This difference would be cost-effective if laparoscopy was at least 10 times
more expensive than MRI. Estimates used at the start of the study placed laparoscopy at being 7.4 times
more expensive than MRI (£1274 vs. £173); however, these NHS tariffs may not necessarily reflect the true
cost of the total investigative pathway, which will be estimated through primary data collection as part of
this study.
Having 250 women as the sample size was also expected to provide a reasonable number of cases of each
of the more common target conditions from which to estimate the sensitivity of MRI for diagnosis. We
anticipated a high sensitivity of MRI for detecting common pathological causes of CPP; therefore, we based
our calculations on an anticipated sensitivity of 80% for any particular condition (a sensitivity of 90% has
also been provided for comparison; Table 4). We then computed the 95% confidence intervals (CIs) for these
sensitivities for a range of prevalences of any particular condition (see Table 4). These figures could equally
apply to specificity. For a target condition with a prevalence of 30% or more, we expected to be able to
reliably rule out a sensitivity or specificity of < 70% if the ‘true’ sensitivity or specificity was > 80%.
In May 2013, when the target sample size had already been slightly exceeded (269 women), the trial team,
together with the input of the independent oversight committees, decided to extend recruitment until the
end of September 2013, with a revised target of 340 women, and the protocol was amended accordingly.
At this stage, the study was recruiting faster than was originally planned. The aim of extending recruitment
was to improve the statistical precision of the accuracy estimates for the less prevalent gynaecological
TABLE 4 Range of 95% CIs for varying prevalences
Assumed sample size of 250 women Assumed sensitivity (%)
Prevalence (%) Number of cases 80 90
50 125 72–87 84–95
40 100 71–87 82–95
30 75 69–88 82–96
20 50 66–90 78–97
METHODS
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causes, and this revised plan was ratified by the external Trial Steering Committee. For example, a sensitivity
of 90% would have a lower 95% CI boundary of 80% for conditions occurring in 30% of women in a
sample size of 250, and in conditions occurring in 20% of women in a sample size of 340. However,
between May 2013 and September 2013, recruitment to the study unexpectedly started to slow and this
revised target was not met, with a final sample size of 291 participants at the start of the diagnostic study.
Data analysis
Reliability estimates
Agreement between the three individual members of the EIP in their diagnosis (for ‘any gynaecological
cause’ and each gynaecological cause separately) was analysed using the methodology proposed by
Fleiss,72 which is a generalisation of the Cohen’s kappa statistic to the measurement of agreement among
multiple raters. In addition, the agreement between the consensus panel diagnosis, made with and
without the MRI findings, was analysed using the Cohen’s kappa agreement statistic. In both cases,
the kappa value was presented alongside its 95% CI. We also reported the number of cases in which
disagreements occurred.
Accuracy estimates
By comparing the index test with the reference standard, the results of the index test were categorised
as a true positive, a false positive, a true negative or a false negative. The sensitivity of each test was
computed as the proportion of all positive results on the reference standard that were true positives, and
the specificity was computed as the proportion of all negative results on the reference standard that were
true negatives.
The prevalence of all gynaecological and non-gynaecological conditions in relation to whether or not they
were believed to be causing pain (as determined by the reference standard established by the consensus
of the EIP) was calculated, along with the 95% CIs, using binomial exact methods.86 For gynaecological
conditions, estimates of prevalence for whether or not the condition was also observed at laparoscopy
were also produced.
The initial analysis looked at the diagnostic accuracy of MRI in being able to detect if a condition actually
existed (regardless of whether or not it was judged to be the cause of pain), using the laparoscopy report
as the reference standard; MRI data were taken directly from the MRI scan report using the set of rules
described in Table 2. Accuracy estimates for this additional analysis (sensitivity and specificity, along with
95% CIs) were calculated, and Fisher’s exact test was used to explore if MRI and laparoscopy detected the
same women with a presence of each target condition.
The primary analysis involved calculations of sensitivity and specificity (and the associated 95% CIs) for the
presence or absence of each structural gynaecological cause of pain; data were taken from the binary
yes/no responses of the reference standard before and after the MRI data were revealed. Receiver
operating characteristic (ROC) curves were also constructed for each test for each condition, using the
certainty estimates (0 = ‘no chance/almost no chance’ to 10 = ‘certain, practically certain’) provided by
the clinician and the binary responses of the reference standard. The area under the ROC (AUROC) curve
and the 95% CI were estimated for each test. Differences between the AUROC estimates of each of
the four diagnoses were then calculated using a non-parametric approach for correlated data,71 and
these differences are presented along with their 95% CIs. The same analysis was done to compare the
responses after the MRI data were revealed (from the independent gynaecologist) with the responses
after the laparoscopy had been undertaken (from the treating gynaecologist), to compare the accuracy
of MRI-based diagnoses with laparoscopy-based diagnoses. Only participants with laparoscopic, MRI and
EIP diagnoses were included in the analysis.
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The proportion of women for whom a diagnostic and/or therapeutic laparoscopy could be avoided was
calculated by adding up the number of women needing treatment other than laparoscopy (women with
adenomyosis, fibroids or PID) and the number of women not needing any treatment (as a result of the
absence of any gynaecological cause), which were correctly identified from the MRI scan.
All analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
METHODS
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Chapter 3 Diagnostic study results
Recruitment
The recruitment of participants started in December 2011 and closed in September 2013. A total of
1667 women were screened. A total of 435 women, who consented to participate, were recruited into the
study from 26 centres (see Appendix 1, Table 29). Ultimately, 287 women contributed to the analysis
(Figure 3).
Exited the diagnostic study
(n = 144)
• Reasons related to MRI (n = 50)
   • Did not attend/cancelled appointment, n = 36
   • Radiology department did not receive MRI
notification, n = 5
   • Patient was claustrophobic, n = 4
   • MRI scan was unblinded owing to abnormality, n = 3
   • MRI sequences were not properly performed, n = 2
• Reasons related to laparoscopy (n = 27)
   • Declined, delayed or did not attend
      appointment, n = 25
   • Lack of theatre sessions, n = 2
• Withdrew from study (n = 22)
   • Did not complete baseline questionnaire, n = 18
   • Withdrew consent, n = 3
   • Registered in error, n = 1
• Other reasons (n = 9)
   • Became pregnant, n = 3
   • Administration error, n = 2
   • Referred to specialist, n = 1
   • Sought private treatment, n = 1
   • Moved home, n = 1
   • Changed mind about any treatment, n = 1
• Missing reasons (n = 36)
Patients excluded
(intraoperative forms not
received on time)
(n = 3)
Patient excluded
(missing data)
(n = 1)
Eligible and consented to
take part
(n = 435)
Management working
diagnosis
(n = 291)
Pre-MRI scan diagnosis
(n = 291)
Post-MRI scan diagnosis
(n = 291)
EIP panel (without MRI)
(n = 287)
Post-laparoscopy
diagnosis
(n = 288)
EIP panel (with MRI)
(n = 287)
Screened
(n = 1667)
FIGURE 3 Flow chart of participants, showing the numbers who provided data at each stage.
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The original sample size of 250 participants was reached ahead of schedule, so the sample size was revised
to 340 participants. The sample size was increased to improve the precision of estimates for all target
conditions, but most notably for the less common target conditions.
Characteristics of participants
The mean age of the women in our sample was 31.6 years [standard deviation (SD) 8.3 years]. Of these,
197 women (68.5%) were in employment and 96 (33.5%) had received a university-level education. There
were 216 white women (74.5%). The duration of pain was, on average, 4.2 years (SD 4.8 years); pain was
present on at least 1 day every week in 226 women (79.5%), with a mean pain score of 7.1 points (SD 2.8
points) during menstrual periods and 6.4 points (SD 2.6 points) before menstrual periods. The average age
at menarche was 12.8 years (SD 1.7 years). Heavy periods were a feature in 147 women (58.6%). Around
three-quarters of women (n = 212; 73.4%) were sexually active, with pain during intercourse featuring
over the last 20.3 months (SD 20.7 months). Contraceptive hormones had been prescribed for pain to
162 women (55.7%). Chlamydia testing was undertaken in 202 women (70.4%), of whom 176 (89.3%)
had received negative results. Laparoscopy and MRI had been used for diagnosis in the past in 80 (27.5%)
and 30 women (10.3%), respectively. Infertility was not a complaint in 206 women (85.1%). Further details
of participant characteristics are shown in Table 5 and Appendix 1, Tables 30 and 31.
The median duration between the MRI scan and the diagnostic laparoscopy was 26 days (interquartile
range of 9–54 days).
Reliability of the expert independent panel diagnoses
We investigated the reliability of the EIP reference diagnoses by looking first at the consensus ratings made
with and without access to the MRI report and, second, at the agreement between individual raters in the
independent expert group.
Table 6 reports the prevalence of each condition as defined by the EIP with and without access to the
MRI report. We considered the primary reference standard to be the EIP consensus statement without the
MRI report, as this would reduce the risk of incorporation bias in assessing the accuracy of the MRI report.
However, we were interested in noting when the reference standard consensus diagnoses differed, as it
was known that an MRI scan may be the only test to identify several of the conditions in some women.
Table 6 shows that the difference in the number of cases detected was between zero and two for all
conditions other than adenomyosis (difference of five cases detected), and cases with psychological
and psychosexual causes (difference of three cases detected). Although there are clinical reasons why
adenomyosis can only be detected by a MRI scan, which are likely to explain the difference, there are no
reasons to explain the difference for cases with psychological and psychosexual causes. We therefore
report comparisons with the second-stage MRI scan-informed EIP consensus reference diagnosis for
analysis of adenomyosis, but not for any other conditions.
To assess the reliability of the EIP diagnoses, we considered the agreement between the three individual
ratings made by the panel members prior to any group discussion. We computed the kappa statistic across
the three raters to describe the agreement beyond that explained by chance. Kappa values above 0.80
were considered to indicate excellent agreement, whereas those between 0.60 and 0.79 indicate good
agreement and those below 0.60 indicate poor or moderate agreement.
DIAGNOSTIC STUDY RESULTS
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The panel were in excellent agreement in identifying deep-infiltrating endometriosis and endometrioma of
the ovary as causes of pelvic pain, and in good agreement in identifying superficial peritoneal endometriosis
and adenomyosis when the MRI reports were used in the reference standard. Lower levels of agreement
were noted for deciding that adhesions, fibroids and PID were the cause of pelvic pain. The expert panel
failed to demonstrate adequate reliability in determining whether any of the non-gynaecological causes
were the cause of pelvic pain for further detailed examination of these causes.
TABLE 5 Characteristics of participants
Characteristic Value
Age (years), mean (SD, n) 31.6 (8.3, 291)
Marital status,a n (%)
Single 96 (33.2)
Living together 66 (22.8)
Married 110 (38.1)
Separated/divorced 17 (5.9)
Employment,b n (%)
Full-time employment 128 (44.4)
Part-time employment 50 (17.4)
Self-employed 19 (6.6)
Caring for children 35 (12.2)
Student 22 (7.6)
Unemployed 34 (11.8)
Highest level of education achieved,c n (%)
No qualifications 17 (5.9)
GCSE/O level/NVQ1–2 94 (32.9)
A level/BTEC qualification/NVQ3–4 79 (27.6)
University degree 67 (23.4)
Postgraduate degree 29 (10.1)
Ethnic group,d n (%)
Asian/Asian British 33 (11.3)
Black/black British 18 (6.2)
White 216 (74.5)
Mixed 12 (4.1)
Any other ethnic group 9 (3.1)
Do not wish to say 2 (0.7)
A level, Advanced level; BTEC, Business and Technology Education Council; GCSE, General Certificate of Secondary
Education; NVQ, National Vocational Qualification; O level, Ordinary level.
a Two missing values.
b Three missing values.
c Five missing values.
d One missing value.
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Prevalence of conditions being the cause of pelvic pain or observed on magnetic
resonance imaging scans or through laparoscopy
Table 7 reports the prevalence of the causes of pelvic pain as judged by the EIP and observed through
laparoscopy and MRI scans. For many conditions (superficial peritoneal endometriosis, endometrioma of
the ovary, adhesions, ovarian cysts, adenomyosis and fibroids), the prevalence of observing the condition
through MRI scans and/or laparoscopy was higher than the prevalence according to the judgements of the
EIP, reflecting that, in many women, the conditions may be observed but not judged to be the cause of
pelvic pain.
Superficial peritoneal endometriosis was identified as the most common gynaecological cause of
pelvic pain in 25% of women, followed by deep-infiltrating endometriosis in 14%, adhesions in 8%,
endometrioma of the ovary, adenomyosis and PID each in 4% and fibroids and ovarian cysts in ≤ 1%.
Of the non-gynaecological causes, psychological/psychosexual causes were the most common in 27% of
women, musculoskeletal causes in 17%, gastrointestinal causes in 8% and urinary causes in 6%. Fifty-four
per cent of women were judged to have idiopathic pelvic pain with no structural gynaecological cause
identified.
The three endometriosis conditions (superficial peritoneal, deep-infiltrating and endometrioma of the
ovary) and ovarian cysts were observed twice as often with laparoscopy, and adhesions three times as
often, as with MRI scans. Adenomyosis, fibroids and PID were noted more often through MRI than
through laparoscopy. No MRI diagnostic criteria were available for the non-gynaecological conditions.
TABLE 6 Reliability of the EIP reference diagnoses
Cause of pelvic pain
Prevalence (N= 287), n (%) Reliability
Reference
diagnosis
without MRI
findings
Reference
diagnosis
with MRI
findings
Assessors’ kappaa
(95% CI)
Number of
cases disputedb
Idiopathic for gynaecological conditions 156 (54.4) 153 (53.3) 0.75 (0.69 to 0.84) 40
Superficial peritoneal endometriosis 71 (24.7) 71 (24.7) 0.74 (0.67 to 0.81) 32
Deep-infiltrating endometriosis 40 (13.9) 42 (14.6) 0.96 (0.89 to 0.99) 3
Endometrioma of the ovary 11 (3.8) 13 (4.5) 0.80 (0.73 to 0.87) 6
Adhesions 24 (8.4) 25 (8.7) 0.54 (0.47 to 0.61) 35
Ovarian cysts 1 (0.3) 0 (0) – 0
Adenomyosis 11 (3.8) 16 (5.6) 0.32 (0.26 to 0.40)
0.60 (0.53 to 0.67)#
24
22#
Fibroids 4 (1.4) 5 (1.7) 0.53 (0.46 to 0.60) 7
PID 10 (3.5) 10 (3.5) 0.52 (0.45 to 0.69) 10
Urinary causes 18 (6.3) 16 (5.6) 0.35 (0.28 to 0.42) 35
Musculoskeletal causes 48 (16.7) 47 (16.4) 0.51 (0.44 to 0.58) 39
Gastrointestinal causes 24 (8.4) 23 (8.0) 0.51 (0.44 to 0.58) 34
Psychological/psychosexual causes 78 (27.2) 75 (26.1) 0.53 (0.46 to 0.59) 59
a Kappa agreement (95% CI) between the three EIP members. Kappa for agreement between the three assessors for the
reference diagnosis made without MRI (stage 1 – see Figure 1) unless indicated # where reference diagnosis including
MRI was used (stage 2 – see Figure 1).
b Number of cases where at least two EIP members disagreed with each other.
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Figure 4 shows the relationships between the causes of pelvic pain based on the EIP diagnoses without the MRI
report for structural gynaecological causes. Superficial peritoneal endometriosis, deep-infiltrating endometriosis
and endometrioma of the ovary often occurred together: 17 out of 40 women with deep-infiltrating
endometriosis also had superficial peritoneal endometriosis, 7 out of 11 women with endometrioma of the
ovary also had deep-infiltrating endometriosis and 7 out of 11 women with endometrioma of the ovary also
had superficial peritoneal endometriosis. Adhesions also appeared in combination with the three types
of endometriosis.
Connecting lines indicate the number of women with both diagnoses. A total of 131 women (46%) had
structural gynaecological causes and are included in Figure 4.
Comparison of observations on magnetic resonance imaging scans against a reference
standard of observations made through laparoscopy
If MRI were to be useful at identifying a condition as being the cause of pelvic pain, it is a prerequisite that
the condition has to be observed in the MRI image. Thus, before investigating the accuracy of MRI for
identification of each condition as a cause, we assessed the accuracy of MRI for observing each condition,
using a reference standard of the condition being observed through laparoscopy. Although this reference
standard was thought to be suitable for identifying the three endometriosis conditions, ovarian cysts and
adhesions, it was unsuitable for use as a reference standard for adenomyosis and fibroids, as it was likely
to miss many cases that could not be identified from inspection of the outside of the uterus. The estimates
of test accuracy for adenomyosis and fibroids should therefore be considered alongside the likelihood of
TABLE 7 Prevalence of conditions being the cause of pelvic pain or observed through MRI scans or laparoscopy
Cause of pelvic pain
Judged as being the cause of pelvic pain,
n (%)
Observation by technique,
n (%)
Reference diagnosis
without MRI
Reference diagnosis
with MRI
Laparoscopy
(N= 287)
MRIa
(N= 287)
Idiopathic (no structural gynaecological
cause)
156 (54.4) 153 (53.3) 75 (26.1) 49 (17.1)b
148 (51.6)c
Superficial peritoneal endometriosis 71 (24.7) 71 (24.7) 120 (41.8) No criteria
Deep-infiltrating endometriosis 40 (13.9) 42 (14.6) 37 (12.9) 3 (1.0)
Endometrioma of the ovary 11 (3.8) 13 (4.5) 68 (23.7) 31 (10.8)
Adhesions 24 (8.4) 25 (8.7) 109 (39.6) 37 (12.9)
Ovarian cysts 1 (0.3) 0 (0) 56 (19.7) 27 (9.4)
Adenomyosis 11 (3.8) 16 (5.6) 21 (7.3) 193 (67.2)b
34 (11.8)c
Fibroids 4 (1.4) 5 (1.7) 24 (8.4) 56 (19.5)
PID 10 (3.5) 10 (3.5) 10 (3.5) 15 (5.2)
Urinary causes 18 (6.3) 16 (5.6) Not assessed No criteria
Musculoskeletal causes 48 (16.7) 47 (16.4) Not assessed No criteria
Gastrointestinal causes 24 (8.4) 23 (8.0) Not assessed No criteria
Psychological/psychosexual causes 78 (27.2) 75 (26.1) Not assessed No criteria
a See Table 2 for definitions used for MRI findings.
b Values when MRI Table 2 definition 1 of adenomyosis is applied.
c Values when MRI Table 2 definition 2 of adenomyosis is applied.
DOI: 10.3310/hta22400 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 40
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Khan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
23
misclassification of cases on the reference standard, as apparent false positives and false negatives could
be caused by misclassification errors in the reference standard, as well as misclassification errors in the
index test. The same concern applied to interpretation of MRI scans judged to be idiopathic, as this was
defined as being the absence of all conditions, including fibroids and adenomyosis. In addition, no criteria
for identifying superficial peritoneal endometriosis or the non-gynaecological conditions on MRI reports
were available, and PID was excluded because few cases were detected.
Table 8 shows that MRI had poor sensitivity for detecting many conditions. MRI detected only 1 of the
36 cases of deep-infiltrating endometriosis that had been observed through laparoscopy (with a sensitivity
of 3%), and picked up 20 of the 107 cases of adhesions (with a sensitivity of 19%), 11 of the 56 cases
of ovarian cysts (with a sensitivity of 20%) and 22 of the 66 cases of endometrioma of the ovary (with a
sensitivity of 33%). The number of false positives (reported on the MRI scan but not seen on laparoscopy)
for these conditions were low, with specificities between 93% and 99%.
We considered two different MRI definitions of adenomyosis (as defined in Table 2), the first of which was
met by 193 women (69%) and the second by 34 women (12%). MRI did not show any relationship with
the findings on laparoscopy for either definition of adenomyosis (p = 0.6 and p = 0.9, respectively). It was
not possible to ascertain if this was attributable to the poor ability of laparoscopy or MRI to detect this
condition. Observing fibroids on MRI scans was closely linked with observing fibroids on laparoscopy
with a sensitivity of 88%, but 35 women had fibroids noted on MRI scans that were not observed on
laparoscopy, which could be explained by the inability of laparoscopy to observe fibroids inside the uterus.
1
1
1
7
1
1
2
2
4
8 17
1
1
7
1
Fibroids
(n = 4)
Superficial peritoneal endometriosis
(n = 71)
Deep-infiltrating
endometriosis
(n = 40)
Adenomyosis
(n = 11)
Ovarian cysts
(n = 1)
PID
(n = 10)
Adhesions
(n = 24)
Endometrioma of the ovary
(n = 11)
FIGURE 4 Relationships between the structural gynaecological causes.
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TABLE 8 Comparison of observations on MRI scans against a reference standard of observations made through laparoscopy
Cause of pelvic pain
MRI
finding
Laparoscopy
finding, n
Sensitivity (95% CI) Specificity (95% CI)
Likelihood ratio (95% CI)
Diagnostic odds
ratio (95% CI)
Test of
associationYes No Positive Negative
Idiopathica Yes 16 33 21.3% (12.7% to 32.3%) 84.4% (78.8% to 89.0%) 1.4 (0.8 to 2.3) 0.9 (0.8 to 1.1) 1.5 (0.8 to 2.8) p= 0.3
No 59 179
Idiopathicb Yes 55 93 73.3% (61.9% to 82.9%) 56.1% (49.2% to 62.9%) 1.7 (1.4 to 2.1) 0.5 (0.3 to 0.7) 3.5 (2.0 to 6.3) p< 0.0001
No 20 119
Superficial peritoneal
endometriosis
Yes 0 0 0% 100% – – – –
No 120 167
Deep-infiltrating
endometriosis
Yes 1 2 2.8% (0.1% to 14.5%) 99.2% (97.1% to 99.9%) 3.5 (0.3 to 37.2) 0.98 (0.93 to 1.04) 3.5 (0.3 to 39.9) p= 0.33
No 35 247
Endometrioma of the
ovary
Yes 22 9 33.3% (22.2% to 46.0%) 95.8% (92.2% to 98.1%) 8.0 (3.9 to 16.5) 0.7 (0.6 to 0.8) 11.5 (5.0 to 26.7) p< 0.0001
No 44 207
Adhesions Yes 20 11 18.7% (11.8% to 27.4%) 93.3% (88.4% to 96.6%) 2.8 (1.4 to 5.6) 0.9 (0.8 to 1.0) 3.2 (1.5 to 6.9) p= 0.003
No 87 154
Ovarian cysts Yes 11 16 19.6% (10.2% to 32.4%) 92.9% (88.7% to 95.9%) 2.8 (1.4 to 5.6) 0.9 (0.8 to 1.0) 3.2 (2.2 to 4.5) p= 0.009
No 45 208
Adenomyosisa Yes 15 175 75.0% (51.0% to 91.0%) 31.9% (26.0% to 38.0%) 1.1 (0.8 to 1.4) 0.8 (0.4 to 1.7) 1.4 (0.5 to 4.0) p= 0.6
No 5 82
Adenomyosisb Yes 2 31 10.0% (1.2% to 31.7%) 87.8% (83.1% to 91.5%) 0.8 (0.2 to 3.2) 1.0 (0.9 to 1.2) 0.8 (0.2 to 3.6) p= 0.9
No 18 222
Fibroids Yes 21 35 87.5% (67.6% to 97.3%) 86.4% (81.6% to 90.4%) 6.5 (4.6 to 9.1) 0.1 (0.05 to 0.4) 44.6 (12.3 to 157.4) p< 0.0001
No 3 223
a Values when MRI Table 2 definition 1 of adenomyosis is applied.
b Values when MRI Table 2 definition 2 of adenomyosis is applied.
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We defined an idiopathic MRI scan to be one in which no criteria for any of the above gynaecological
conditions were met. As we considered two alternative MRI definitions of adenomyosis, there were two
corresponding definitions of ‘idiopathic’. The first MRI definition categorised the majority of women as
having adenomyosis, with only 49 women (18%) judged to have an idiopathic MRI report, and this finding
showed no relationship with observing no structural gynaecological cause on laparoscopy (p = 0.3; see
Appendix 2, Table 32).
Using the second definition, 148 women (52%) were categorised as having an idiopathic MRI report, of
whom 93 had findings on laparoscopy. Twenty women, defined as idiopathic on laparoscopy, were noted
to meet the criteria for a gynaecological condition using MRI. Overall, the idiopathic diagnoses made
through laparoscopy and MRI were in agreement in only 61% of women (see Appendix 2, Table 33).
Comparison of observations made using magnetic resonance imaging against the expert
panel reference standard for the cause of pelvic pain
In a further analysis, we considered whether or not MRI findings were diagnostic of the cause of pelvic pain
as stated by the EIP. We compared with the EIP consensus diagnosis based on information excluding MRI
for all conditions other than adenomyosis where consensus diagnoses including information from MRI was
used (Table 9). Most conditions on MRI reports were less likely to be regarded as a cause of pelvic pain than
conditions observed on laparoscopy; using MRI reports, superficial peritoneal endometriosis was rated as a
cause of pain in 71 women, whereas it was observed in 120 women on laparoscopy; endometrioma of the
ovary was noted as a cause in 11 women, but observed in 66 women; adhesions was a cause in 24 women,
while noted in 107 women; ovarian cysts was a cause in only 1 woman, but noted in 56 women; adenomyosis
was a cause in 16 women, but noted in 20 women; and fibroids was a cause in 4 women, while noted in
24 women. The only exceptions were deep-infiltrating endometriosis, which was regarded as a cause of pain
in 39 women, but only noted in 36 women, and idiopathic (lack of a gynaecological structural cause), which
was concluded in only 75 women on laparoscopy, but was the conclusion of the EIP in 156 women.
The accuracy of MRI to identify the cause of pelvic pain was inestimable for superficial peritoneal endometriosis
and non-gynaecological causes, as no MRI definitions were available. Estimates of test sensitivity for ovarian
cysts and fibroids were based on only one and four cases, respectively, and thus were very imprecise.
The sensitivity of MRI for detecting deep-infiltrating endometriosis as a cause of pelvic pain was very low
(3%), but close to 80% for endometrioma of the ovary (albeit with wide CIs). The sensitivity for adhesions
and adenomyosis using the second definition was between 40% and 50%. For all these conditions,
specificity was around 90%.
There was no significant relationship between the MRI findings and the expert panel findings drawing an
idiopathic conclusion for the cause of pelvic pain for either definition (p = 0.9 and p = 0.08, respectively).
For the second definition (using the more stringent definition of adenomyosis), 159 out of 287 MRI
findings and expert consensus classifications of whether the chronic pain was idiopathic or structural
(55%) were in agreement.
The impact of magnetic resonance imaging on confidence and accuracy in
making diagnoses
The independent gynaecologist rated the likelihood of each cause of CPP first when provided with all
baseline data (including ultrasound reports) and, second, when additionally provided with the report from
the MRI scan. This allows an assessment to be made of the degree to which the MRI scan provided additional
diagnostic information over and above that available from the baseline assessments. The independent
gynaecologist was not provided with the MRI criteria stated in Table 2, but was provided wih only the
measurements made on MRI and the textual report. Each independent gynaecologist rated their certainty that
each condition was causing pelvic pain on a scale of 0 (no chance) to 10 (certain). We deduced the certainty
that the diagnosis was idiopathic by subtracting the highest score for the gynaecological structural causes
from 10. The results for scores of 0–3, 4–6 and 7–10 are presented in Table 9, along with the likelihood ratios
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TABLE 9 Comparison of observations made using MRI against the expert panel reference standard for the cause of pelvic pain
Cause of pelvic pain
MRI
finding
Expert panel
consensus, n
Sensitivity (95% CI) Specificity (95% CI)
Likelihood ratio (95% CI)
Diagnostic odds
ratio (95% CI)
Test of
associationYes No Positive Negative
Idiopathica Yes 26 23 16.7% (11.2% to 23.5%) 82.4% (74.8% to 88.5%) 0.9 (0.6 to 1.6) 1.0 (0.9 to 1.1) 0.9 (0.5 to 1.7) p= 0.9
No 130 108
Idiopathicb Yes 88 60 56.4% (48.3% to 64.3%) 54.2% (45.3% to 62.9%) 1.2 (0.9 to 1.5) 0.8 (0.6 to 1.0) 1.5 (0.9 to 2.4) p= 0.08
No 68 71
Superficial peritoneal
endometriosis
Yes – – – – – – – –
No 71 216
Deep-infiltrating
endometriosis
Yes 1 2 2.6% (0.1% to 13.5%) 99.2% (97.1% to 99.9%) 3.15 (0.29 to 34.0) 0.98 (0.93 to 1.03) 3.21 (0.28 to 36.30) p= 0.36
No 38 244
Endometrioma
of ovary
Yes 9 22 81.8% (48.2% to 97.7%) 91.9% (88.0% to 94.8%) 10.1 (6.2 to 16.4) 0.2 (0.1 to 0.7) 50.9 (10.4 to 250.5) p< 0.0001
No 2 249
Adhesions Yes 9 28 37.5% (18.8% to 59.4%) 89.2% (84.8% to 92.7%) 3.5 (1.9 to 6.5) 0.7 (0.5 to 0.9) 5.0 (2.0 to 12.4) p= 0.001
No 15 232
Ovarian cysts Yes 0 27 0% (0% to 97.5%) 90.4% (86.3% to 93.6%) – – – p= 0.9
No 1 254
Adenomyosisa [post
MRI EIPc]
Yes 9 (15) 184 (178) 81.8% (48.2% to 97.7%) 31.6% (26.1% to 37.5%) 1.2 (0.9 to 1.6) 0.6 (0.2 to 2.0) 2.0 (0.4 to 9.8) p= 0.5
No 2 (1) 85 (86) [93.8% (70.0% to 99.8%)] [32.6% (27.0% to 38.6%)] [1.4 (1.2 to 1.6)] [0.2 (0.03 to 1.3)] [7.2 (0.9 to 55.8)] [p= 0.03]
Adenomyosisb [post
MRI EIPc]
Yes 0 (7) 34 (27) 0% (0% to 30.8) 87.2% (82.6% to 91.0%) 0 (–) 1.15 (1.1 to 1.2) 0 (–) p= 0.6
No 10 (8) 232 (234) [46.7% (21.3% to 73.4%)] [89.7% (85.3% to 93.1%)] [4.5 (2.4 to 8.6)] [0.6 (0.4 to 0.9)] [7.6 (2.6 to 22.6)] [p= 0.001]
Fibroids Yes 4 52 100% (39.8 to 100) 81.4% (76.4 to 85.8) 5.4 (4.2 to 6.9) 0 (–) – (–) p= 0.001
No 0 228
a Values when MRI Table 2 definition 1 of adenomyosis is applied.
b Values when MRI Table 2 definition 2 of adenomyosis is applied.
c Results for adenomyosis are compared first with the reference panel consensus without MRI findings and, second, with the reference panel consensus diagnosis with MRI findings.
D
O
I:10.3310/hta22400
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2018
VO
L.22
N
O
.40
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2018.
This
w
ork
w
as
produced
by
K
han
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
27
computed to indicate the degree to which high (or low) scores rule each condition in (or out). We measured
the diagnostic accuracy across all scores by plotting ROC curves for each condition (Figure 5) and summarised
the accuracy as the AUROC value. The likelihood ratio and AUROC values were computed for assessments
made on baseline evidence alone, and then made with the additional provision of the MRI report; the
incremental diagnostic value of the MRI scan is summarised using the change in the AUROC value and by
comparing the likelihood ratio values.
An AUROC value of 0.5 would be obtained if diagnoses were made by chance, whereas a test with perfect
discrimination would have a value of 1.0. The baseline values of the AUROC were not significantly different
from 0.5 for all conditions except adhesions (AUROC value of 0.64), indicating that the independent
gynaecologist was not significantly better than chance in producing a diagnosis that agreed with that of the
EIP, and only had a weak relationship for adhesions. Provision of the MRI report improved the accuracy of all
diagnoses, but the increase in AUROC value was only statistically significant for deep-infiltrating endometriosis
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FIGURE 5 Accuracy of assessments of the cause of pelvic pain pre and post MRI and laparoscopy: ROC curves
for comparison. (a) Idiopathic; (b) superficial peritoneal endometriosis; (c) deep-infiltrating endometriosis;
(d) endometrioma of the ovary; (e) adhesions; and (f) adenomyosis (reference standard with MRI). (continued )
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FIGURE 5 Accuracy of assessments of the cause of pelvic pain pre and post MRI and laparoscopy: ROC curves
for comparison. (a) Idiopathic; (b) superficial peritoneal endometriosis; (c) deep-infiltrating endometriosis;
(d) endometrioma of the ovary; (e) adhesions; and (f) adenomyosis (reference standard with MRI). (continued )
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(p = 0.006) and endometrioma of the ovary (p = 0.02). Likelihood ratios for scores in the 4–6 and 7–10
categories deep-infiltrating endometriosis and endometrioma of the ovary were around 4–7, which are not
high enough to convincingly rule in these diagnoses. Although scores of 7–10 for adhesions had the highest
likelihood ratio, at 7.3, they were made in only 15 women, and detected in only 30% of those with
adhesions as a cause of pelvic pain (Table 10).
Accuracy of assessments of the cause of pelvic pain pre and post MRI and laparoscopy
Table 11 allows comparisons to be made between the findings from MRI and laparoscopy. As for
assessment of the incremental diagnostic value of MRI, we report values for the AUROC, the change in
AUROC and the likelihood ratios to describe diagnostic accuracy.
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FIGURE 5 Accuracy of assessments of the cause of pelvic pain pre and post MRI and laparoscopy: ROC curves
for comparison. (a) Idiopathic; (b) superficial peritoneal endometriosis; (c) deep-infiltrating endometriosis;
(d) endometrioma of the ovary; (e) adhesions; and (f) adenomyosis (reference standard with MRI).
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TABLE 10 Impact of MRI on confidence in, and accuracy of, diagnoses made
Cause of pelvic pain
Diagnostic
confidence
score
Rating
Change in AUROC
(95% CI; p-value)
Before MRI results revealed After MRI results revealed
Expert panel
consensus, n
Likelihood ratio
(95% CI) AUROC (95% CI)
Expert panel
consensus, n
Likelihood
ratio (95% CI) AUROC (95% CI)Yes No Yes No
Idiopathic 7–10 53 43 1.0 (0.7 to 1.4) 0.53 (0.46 to 0.60) 77 44 1.5 (1.1 to 2.0) 0.60 (0.53 to 0.67) +0.07 (–0.01 to 0.15;
p= 0.06)
4–6 86 69 1.0 (0.8 to 1.3) 49 47 0.9 (0.6 to 1.2)
0–3 17 19 0.8 (0.4 to 1.4) 30 40 0.6 (0.4 to 1.0)
Superficial peritoneal
endometriosis
7–10 9 13 2.1 (0.9 to 4.7) 0.54 (0.46 to 0.61) 5 10 1.5 (0.5 to 4.3) 0.56 (0.49 to 0.64) +0.02 (–0.05 to 0.10;
p= 0.5)
4–6 28 92 0.9 (0.7 to 1.3) 19 54 1.1 (0.7 to 1.7)
0–3 34 111 0.9 (0.7 to 1.2) 47 152 0.9 (0.8 to 1.1)
Deep-infiltrating
endometriosis
7–10 1 2 3.1 (0.3 to 33.3) 0.53 (0.43 to 0.62) 5 6 5.1 (1.7 to 9.4) 0.66 (0.57 to 0.76) +0.13 (0.04 to 0.23;
p= 0.006)
4–6 9 42 1.3 (0.7 to 2.5) 8 12 4.1 (1.8 to 9.4)
0–3 30 203 0.9 (0.8 to 1.1) 27 229 0.7 (0.6 to 0.9)
Endometrioma of the
ovary
7–10 0 2 0 0.58 (0.44 to 0.71) 2 8 6.3 (1.5 to 26.1) 0.78 (0.62 to 0.95) +0.20 (0.02 to 0.39;
p= 0.02)
4–6 0 24 0 4 14 7.2 (2.8 to 18.2)
0–3 11 250 1.1 (1.0 to 1.2) 5 254 0.5 (0.3 to 0.9)
Adhesions 7–10 1 5 2.2 (0.3 to 18.0) 0.64 (0.53 to 0.75) 6 9 7.3 (2.8 to 18.8) 0.72 (0.60 to 0.83) +0.08 (–0.03 to 0.18;
p= 0.2)
4–6 5 39 1.4 (0.6 to 3.2) 6 37 1.8 (0.8 to 3.8)
0–3 18 219 0.9 (0.7 to 1.1) 12 217 0.6 (0.4 to 0.9)
Adenomyosis (post-
MRI EIP consensus)
7–10 2 7 4.8 (1.1 to 21.4) 0.53 (0.36 to 0.71) 6 22 4.6 (2.2 to 9.8) 0.68 (0.50 to 0.85) +0.15 (–0.03 to 0.32;
p= 0.1)
4–6 3 80 0.6 (0.2 to 1.8) 4 41 1.7 (0.7 to 4.0)
0–3 11 184 1.0 (0.7 to 1.4) 6 208 0.5 (0.3 to 0.9)
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TABLE 11 Difference between MRI and laparoscopy on confidence in, and accuracy of, diagnoses made
Cause of pelvic pain
Diagnostic
confidence
score
Rating after
Change in AUROC
(95% CI; p-value)
MRI results are revealed Laparoscopy
Expert panel
consensus, n
Likelihood ratio
(95% CI) AUROC (95% CI)
Expert panel
consensus, n
Likelihood ratio
(95% CI) AUROC (95% CI)Yes No Yes No
Idiopathic 7–10 77 44 1.5 (1.1 to 2.0) 0.60 (0.53 to 0.67) 81 4 17.6 (6.6 to 46.6) 0.80 (0.75 to 0.86) +0.20 (0.12 to 0.28;
p< 0.0001)
4–6 49 47 0.9 (0.6 to 1.2) 26 18 1.3 (0.7 to 2.2)
0–3 30 40 0.6 (0.4 to 1.0) 44 109 0.4 (0.3 to 0.5)
Superficial peritoneal
endometriosis
7–10 5 10 1.5 (0.5 to 4.3) 0.56 (0.49 to 0.64) 54 38 4.2 (3.1 to 5.7) 0.87 (0.83 to 0.91) +0.31 (0.22 to 0.39;
p< 0.0001)
4–6 19 54 1.1 (0.7 to 1.7) 12 15 2.4 (1.2 to 4.8)
0–3 47 152 0.9 (0.8 to 1.1) 5 156 0.1 (0.04 to 0.2)
Deep-infiltrating
endometriosis
7–10 5 6 5.1 (1.7 to 9.4) 0.66 (0.57 to 0.76) 33 6 33.0 (14.7 to 73.3) 0.95 (0.90 to 0.99) +0.29 (0.16 to 0.35;
p< 0.0001)
4–6 8 12 4.1 (1.8 to 9.4) 3 5 3.6 (0.9 to 14.4)
0–3 27 229 0.7 (0.6 to 0.9) 4 228 0.1 (0.04 to 0.3)
Endometrioma of
ovary
7–10 2 8 6.3 (1.5 to 26.1) 0.78 (0.62 to 0.95) 9 10 21.8 (11.2 to 42.6) 0.97 (0.95 to 0.99) +0.19 (0.03 to 0.36;
p= 0.02)
4–6 4 14 7.2 (2.8 to 18.2) 1 7 3.5 (0.5 to 25.7)
0–3 5 254 0.5 (0.3 to 0.9) 1 250 0.1 (0.01 to 0.6)
Adhesions 7–10 6 9 7.3 (2.8 to 18.8) 0.72 (0.60 to 0.83) 12 39 3.3 (2.0 to 5.4) 0.82 (0.74 to 0.90) +0.10 (–0.05 to 0.26;
p= 0.2)
4–6 6 37 1.8 (0.8 to 3.8) 7 28 2.7 (1.3 to 5.4)
0–3 12 217 0.6 (0.4 to 0.9) 5 189 0.3 (0.1 to 0.6)
Adenomyosis (post-
MRI EIP consensus)
7–10 6 22 4.6 (2.2 to 9.8) 0.68 (0.50 to 0.85) 1 12 1.5 (0.2 to 10.5) 0.52 (0.38 to 0.67) –0.15 (–0.33 to 0.02;
p= 0.09)
4–6 4 41 1.7 (0.7 to 4.0) 1 25 0.7 (0.1 to 4.8)
0–3 6 208 0.5 (0.3 to 0.9) 13 226 1.0 (0.8 to 1.2)
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The accuracy of diagnoses of the causes of pelvic pain made by laparoscopy was high for superficial
peritoneal endometriosis (AUROC = 0.87), deep-infiltrating endometriosis (AUROC = 0.95) and
endometrioma of the ovary (AUROC = 0.97). Certainty scores of 7 and above could accurately rule for
deep-infiltrating endometriosis [LR (likelihood ratio) = 33] and endometrioma of the ovary (LR = 22),
and low scores of 0–3 could rule out all three conditions (LR = 0.1).
Poorer performance was noted for laparoscopy diagnoses of idiopathic pelvic pain (AUROC = 0.80) and of
adhesions being the cause of pelvic pain (AUROC = 0.82). However, a high score for idiopathic pelvic pain
(computed as 10 minus the highest score for any other condition) provided convincing evidence (LR = 18)
to rule in an idiopathic diagnosis. Laparoscopy was no better than chance in diagnosing adenomyosis as
the cause of pelvic pain (AUROC = 0.52).
For four diagnoses (idiopathic pelvic pain, superficial peritoneal endometriosis, deep-infiltrating endometriosis
and endometrioma of the ovary), laparoscopy was significantly more accurate than MRI-based diagnoses in
identifying the cause of pelvic pain.
However, there are two reasons to consider these comparisons as being at risk of bias, and that they
may potentially overestimate the magnitude of differences between the tests in favour of laparoscopy.
First, Figure 5 shows that the ROC curves for baseline assessments made by the treating gynaecologist
(labelled ‘baseline’) and the independent gynaecologist (labelled ‘pre MRI’), based on the same information
obtained from history, examination and ultrasound, are not comparable. For all six conditions presented in
Figure 5, the treating gynaecologist had superior diagnostic accuracy to the independent gynaecologist,
which possibly reflects that the diagnoses of the treating clinician benefited from direct interaction with
the patient, which the blinded independent gynaecologist lacked (more detail on idiopathic CPP diagnoses
is given in Appendix 2, Tables 34 and 35). Given that the post-laparoscopy and post-MRI diagnoses were
made by the treating gynaecologist and the independent gynaecologist, respectively, the bias introduced
by this is likely to have led to overestimation of the difference.
Second, the EIP had access to the laparoscopy findings when making their reference diagnoses for all
conditions, which is likely to have introduced a degree of incorporation bias, leading to overestimation of
the accuracy of laparoscopy.
The diagnoses of adhesions showed no significant differences in accuracy between any of the four
diagnoses for adhesions. This is likely, in part, to be explained by misclassification in the reference standard,
which is suspected through the low agreement rates observed between the assessors (see Table 6).
Adenomyosis was the only diagnosis of CPP for which the post MRI test accuracy was superior to the post
laparoscopy accuracy, despite the difference not being statistically significant. Intriguingly, the diagnosis of
adenomyosis made by the recruiting clinician prior to either test was found to be the most accurate.
Use and recommendations for therapeutic laparoscopy
For the final analyses, women were categorised according to whether or not they would benefit from
therapeutic laparoscopy. A test pathway incorporating MRI prior to laparoscopy would be of benefit
to women should it correctly identify women who do not require therapeutic laparoscopy, as this is
commonly undertaken during the diagnostic laparoscopic procedure.
Table 12 compares the accuracy of diagnoses made post MRI for the key conditions indicating the need
for therapeutic laparoscopy, and the recommendations for therapeutic laparoscopy by the independent
gynaecologist, following their assessment of the MRI report. Fifty-two out of the 112 women (46%) with
the key conditions indicating the need for therapeutic laparoscopy were rated with diagnostic confidence
scores of 5 or higher, although the independent gynaecologist rated more women (78/112; 70%) as
potentially benefiting from a therapeutic laparoscopy, having seen the MRI report. Women with superficial
peritoneal endometriosis were the most poorly identified.
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Of the 175 women with gynaecological conditions for which therapeutic laparoscopy would have no clear
benefit, non-gynaecological conditions or no structural cause, the post-MRI diagnosis rated 104 (59%)
with confidence scores of 5 or above for these conditions (with lower ratings for any endometriosis or
adhesions). However, 116 out of the 175 women (66%) were rated as being likely to benefit from
therapeutic laparoscopy, based on the interpretation of the MRI report by the independent gynaecologist.
Table 13 compares the ability of the independent gynaecologist to correctly identify women who would,
and women who would not, benefit from therapeutic laparoscopy for three situations: (1) if a woman
received an EIP diagnosis of superficial endometriosis, deep-infiltrating endometriosis, endometrioma of
the ovary or adhesions; (2) if the EIP directly rated a woman as being likely to benefit from a therapeutic
laparoscopy; and (3) if a woman was recorded on the operative sheet as having received a therapeutic
component during the study laparoscopy.
For all three comparisons, the MRI assessment identified 70% of women categorised as requiring
therapeutic laparoscopy (sensitivity). However, the MRI assessment wrongly suggested that two-thirds
of women not meeting these criteria did require therapeutic laparoscopy (specificity).
Inspection of the predictive values provides information on the number of errors in decision-making that
would be made should the MRI report be used to inform the decision to progress to laparoscopy. As the
three criteria were met by increasing proportions of women [the first criterion was met by 112 women
(39%), the second by 127 women (44%) and the third by 167 women (58%)], the predictive values of
MRI recommendations changed according to the comparison that was made (see Table 13).
TABLE 12 Use and recommendations for therapeutic laparoscopy
Cause of pelvic pain
Prevalence,
% (reference
standard)
Therapeutic laparoscopy,
n (%)
Diagnostic confidence score post MRI
test, n (%)
Recommended
by the EIP
Performed
(two missing) ≥ 3 ≥ 5 ≥ 7
Therapeutic
laparoscopy
recommended
following MRI
test
Conditions for which therapeutic laparoscopy is recommended
Superficial
endometriosis
71 (24.7) 69 (97) 58 (83) 48 (68) 13 (18) 5 (7) 49 (69)
Deep-infiltrating
endometriosis
40 (13.9) 38 (95) 31 (78) 14 (35) 9 (23) 5 (13) 30 (75)
Endometrioma of the
ovary
11 (3.8) 11 (100) 10 (91) 7 (64) 6 (55) 2 (18) 10 (91)
Any endometriosis 96 (33.5) 92 (96) 78 (82) 70 (73) 35 (36) 16 (17) 67 (70)
Adhesions 24 (8.4) 23 (96) 18 (75) 14 (58) 10 (42) 6 (25) 18 (75)
Any endometriosis,
adhesions or ovarian
cysts
112 (39.0) 106 (95) 92 (83) 91 (81) 52 (46) 31 (28) 78 (70)
Conditions for which therapeutic laparoscopy is not recommended
Idiopathic 72 (25.0) 13 (18) 34 (47) 60 (83) 36 (50) 8 (11) 49 (68)
Non-gynaecological
cause only
90 (31.0) 7 (8) 36 (40) 81 (90) 41 (46) 13 (14) 59 (66)
Anything other than
endometriosis or
adhesions or ovarian
cysts
175 (61.0) 21 (12) 75 (43) 165
(94)
104
(59)
44 (25) 116 (66)
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First, compared with an EIP recommendation that a woman would benefit from therapeutic laparoscopy,
a recommendation based on the MRI findings to proceed to laparoscopy would be correct only for 45%
of women: 55% would undergo the procedure unnecessarily. In comparison, the alternative pathway
of all women receiving laparoscopy leads to 56% of women receiving the procedure unnecessarily. A
recommendation to not proceed to laparoscopy would be correct in 58% of women, whereas 42% of
women not receiving laparoscopy would have benefited from it.
Extrapolating from these figures, and assuming the same prevalence of conditions, in a cohort of 1000 women,
deciding to proceed to laparoscopy based on MRI findings would lead to 369 women who did not require
laparoscopy receiving it, and 136 women who did require laparoscopy not receiving it. In a ‘laparoscopy for all’
strategy, 557 women who did not require laparoscopy would receive it.
If we compare the recommendation for therapeutic laparoscopy from the MRI findings against the actual
diagnoses made by the EIP, the number of women receiving laparoscopy unnecessarily would increase to
404 per 1000 women, and the number of women not receiving laparoscopy who did require it would
decrease to 118. If the comparison was made against the actual use of therapeutic laparoscopy, the
number of women receiving laparoscopy unnecessarily would decrease to 264 per 1000 women, and the
number not receiving laparoscopy who did require it would increase to 174.
TABLE 13 Independent gynaecologist determination of benefit from therapeutic laparoscopy
Therapeutic laparoscopy
recommended following
MRI test
EIP-identified condition
amenable to therapeutic
laparoscopy
Therapeutic laparoscopy
recommended by the EIP
Therapeutic laparoscopy
performed
Yes No Yes No Yes No
Yes, n 78 116 88 106 117 76
No, n 34 59 39 54 50 42
Sensitivity (95% CI) 69.6% (60.2% to 78.0%) 69.3% (60.5% to 77.2%) 70.1% (62.5% to 76.9%)
Specificity (95% CI) 33.7% (26.8% to 41.2%) 33.8% (26.5% to 41.6%) 35.6% (27.0% to 44.9%)
PPV (95% CI) 40.2% (33.2% to 47.5%) 45.4% (38.2% to 52.6%) 60.6% (53.3% to 67.6%)
NPV (95% CI) 63.4% (52.8% to 73.1%) 58.1% (47.4% to 68.2%) 45.7% (35.2% to 56.4%)
NPV, negative predictive value; PPV, positive predictive value.
DOI: 10.3310/hta22400 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 40
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Khan et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35

Chapter 4 Economic evaluation
Introduction
One of the factors that contributes to the lack of speedy diagnosis of CPP among women is that laparoscopy is
perceived to be an invasive, expensive and potentially risky procedure, and that it is used far too frequently in
the NHS, as a significant proportion of women have no pathology identified.73 MRI represents a less invasive
and, potentially, less expensive procedure than laparoscopy, and as such may be the preferred option for the
woman or for the health-care provider. However, as shown in previous chapters of this report, the test accuracy
of diagnostic laparoscopy in detecting the structural causes of CPP is greater than that for MRI, meaning that
women are more likely to be properly diagnosed and then access the appropriate treatment following a
diagnostic laparoscopy than with a MRI scan. In this chapter, all of these factors are considered as part of a
wider cost-effectiveness analysis, the objective of which is to examine the cost-effectiveness of MRI compared
with diagnostic laparoscopy in women with undiagnosed CPP. However, the study design used in the research
meant that all women received all tests, and from the data collected, ROC curves were obtained for both MRI
and laparoscopy which could then inform their sensitivity and specificity values based on alternative cut-off
points. This meant that the actual sensitivity and specificity values for laparoscopy, as used in usual practice,
could not be informed by this study, and so consequently it was not possible to parameterise a usual-practice
scenario in this economic analysis. Therefore, we consider MRI and laparoscopy with alternative sensitivity and
specificity pairs (as informed by the ROC curves) as separate strategies and examine which test and sensitivity
and specificity values is the most cost-effective for women with CPP. For completeness, we also compare these
strategies with a no-testing scenario, in which a patient receives neither MRI nor laparoscopy.
Methods
Developing the model structure
The comparison of the pathways undertaken by women in this study is best represented in a modelling
framework, in which the alternative pathways that women can follow are compared in order to diagnose
the cause of their CPP. As all women in the MEDAL study were tested with MRI scans and diagnostic
laparoscopy, a model was required to simulate the outcomes of each of the patient pathways when only
one test was administered. A model allows explicit representation of the impact of the accuracy of the
tests, the costs to the health service and the impact on the health-related QoL experienced by the women
undergoing a particular pathway.
A model was developed via consultation with the research team, drawing on key clinical and modelling
expertise. A decision tree was applied using TreeAge Pro 2001 software (TreeAge Software, Inc., Williamstown,
MA, USA). A 6-month time horizon was adopted, as this was the period of data collection, and, given that
there was very little chance of events recurring on the patient pathways (such as a patient receiving multiple
laparoscopies), it was felt that this approach was the most appropriate.
Women entered the model having been identified as having CPP and being eligible for diagnostic
laparoscopy. Two different patient pathways were compared, which describe alternative approaches to the
diagnosis and treatment of the causes of CPP, a summary of which can be found in Figure 6. Figures 7–10
show the patient pathways considered in this analysis, which together form the model structure for the
decision tree used in the cost-effectiveness analysis. For both pathways, a baseline examination was
conducted, which comprised a patient history followed by a physical examination, and an ultrasound scan
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Patients with CPP who were eligible for laparoscopy
Patients given baseline examination
Decision: MRI or laparoscopy, depending on the patient pathway
Patient offered MRI Ineligible/refused: 
follow laparoscopy pathway
False negativeTrue negative
Patient offered laparoscopy
Test positive: given
therapeutic laparoscopy
or other treatment
Did not accept
laparoscopy
Patients may (1) have improvement in their quality of life if properly diagnosed and
treated, (2) remain in a decreased state of health if subject to a false-negative result
or (3) maintain their quality of life if no cause of CPP was found to be present
True negative False negative
FIGURE 6 Women with CPP who were eligible for laparoscopy, who received either MRI or laparoscopy.
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Patients
Laparoscopy
All patients
receive baseline
examination
CPP cause, fibrosis/
adenomyosis: positive
CPP cause negative
Receives a
diagnostic
laparoscopy
Receives a
diagnostic
laparoscopy
Yes
No
Yes
No
True positive
False negative
Hysterectomy
LNG-IUS
Fibrosis treatment
CPP cause treatable by
therapeutic laparoscopy:
positive
MRI
True positive:
therapeutic laparoscopy
given during same
procedure
False negative
Yes
No: given in
subsequent
procedure
FIGURE 7 Model structure for the laparoscopy treatment arm for women who tested positive for a structural cause of CPP. LNG-IUS, levonorgestrel-releasing intrauterine system.
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Patients
Laparoscopy
All patients
receive baseline
examinationMRI
Hysterectomy
LNG-IUS
Fibrosis- 
treatment
Yes
No
Yes
No
No: given in
subsequent
procedure
Hysterectomy
LNG-IUS
Fibrosis
treatment
False negative
True positive
Has diagnostic
laparoscopy
Has diagnostic
laparoscopy
False negative
True positive
False negative
True positive
Therapeutic
laparoscopy offered:
accepted
True positive:
therapeutic
laparoscopy given
during same
procedure
False negative
Yes
No
Yes
CPP cause
negative
CPP cause
fibrosis
adenomyosis:
positive
Eligible and
receives MRI
CPP cause treatable
by therapeutic
laparoscopy:
positive
Eligible and
receives MRI
FIGURE 8 Model structure for the MRI treatment arm for women who tested positive for a structural cause of CPP. LNG-IUS, levonorgestrel-releasing intrauterine system.
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Patients
Laparoscopy
All patients
receive baseline
examination
CPP cause, fibrosis/
adenomyosis: positive
CPP cause negative
Receives
diagnostic
laparoscopy
Yes
No
False positive: other
treatment
False positive:
therapeutic
laparoscopy
True negative
During diagnostic
laparoscopy
In subsequent
procedure
Hysterectomy
LNG-IUS
Fibrosis treatment
CPP cause treatable by
therapeutic laparoscopy:
positive
MRI
FIGURE 9 Model structure for the laparoscopy treatment arm for women who tested negative for a structural cause of CPP. LNG-IUS, levonorgestrel-releasing intrauterine system.
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Patients
Laparoscopy
All patients
receive baseline
examination
Has diagnostic
laparoscopy
MRI
CPP cause
negative
Eligible and
receives MRI
Yes
No
Hysterectomy
LNG-IUS
Fibrosis
treatment
CPP cause, fibrosis
adenomyosis:
positive
CPP cause treatable by
therapeutic laparoscopy:
positive
Yes
No
False positive:
other treatment
False positive:
therapeutic
laparoscopy
Therapeutic
laparoscopy
given during
same procedure
True negative: no
further treatment given
False positive
True negative
FIGURE 10 Model structure for the MRI treatment arm for women who tested negative for a structural cause of CPP. LNG-IUS, levonorgestrel-releasing intrauterine system.
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when clinically indicated. The remainder of the pathway followed either the laparoscopy pathway or the
MRI pathway.
Laparoscopy pathway
Women were offered a diagnostic laparoscopy, which may or may not have been accepted. For those
women who received the diagnostic laparoscopy, this would give either a positive or a negative result for
the presence of a structural cause of CPP. For those who tested positive for a cause that required a
therapeutic laparoscopy, this would be given during the same or a subsequent procedure. For women who
tested positive for a structural cause that required other treatment, in this case fibroids or adenomyosis,
this treatment would be subsequently administered. For those women who tested negative, no further
tests or treatment would be administered, and if this was a false-negative test result, then the patient
would remain in a decreased state of health (see Figures 7 and 9).
Magnetic resonance imaging pathway
Women were offered a MRI scan that may or may not have been accepted; women who rejected or were
ineligible for a MRI scan would then follow the laparoscopy pathway (see Figures 8 and 9). Women who
received a MRI scan and a positive test result were given a therapeutic laparoscopy or other treatment, as
appropriate. For women who tested negative, no further tests or treatments were administered and, again, if
the test result was false negative, these women would remain in a decreased state of health (see Figure 10).
No testing (neither magnetic resonance imaging nor laparoscopy)
A no-testing scenario was incorporated into this analysis, which was assumed to consist of a baseline
examination (see Model assumptions). Although we acknowledge that this strategy would not be
considered in practice for this patient group, the inclusion of no testing is important for comparative
purposes, and can show whether or not a testing strategy is more harmful than no testing.
Model assumptions
In order to implement a working model structure and enable this analysis to be carried out, a number of model
assumptions were necessary. These assumptions were broadly categorised as being related to resource use/
costs, diagnostic pathway, course of treatment and QoL, and are described, as follows, in the next sections.
Resource use/costs
l The baseline examination given to all women at the start of each strategy (including no testing)
consisted of the following procedures:
¢ patient history taken by a research nurse and consultant, which takes 20 minutes
¢ physical examination undertaken by a consultant, which takes 20 minutes
¢ an abdominal and vaginal ultrasound (for two-thirds of women).
l A patient would receive one consultation prior to each laparoscopy, and then one consultation post
laparoscopy, each taking 20 minutes with a consultant.
l To allow for the increased likelihood of complications related to therapeutic laparoscopy, therapeutic
laparoscopy was assumed to cost 10% more than diagnostic laparoscopy.
Diagnostic pathway
l Only women with a structural cause of CPP were regarded as having a true-positive diagnosis and
being in need of treatment.
l A patient who received a false-positive result from a diagnostic laparoscopy would receive therapeutic
laparoscopy during the same or a subsequent procedure.
l A patient who received a false-negative test result would receive no further testing or treatment and
would remain in a decreased state of health for the remainder of the time horizon of the analysis.
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l Women would always accept a laparoscopy following a positive MRI result.
l A patient would always accept a diagnostic laparoscopy after having refused or having been ineligible
for a MRI scan.
Course of treatment
l For women with adenomyosis, 50% had a hysterectomy and 50% had a levonorgestrel-releasing
intrauterine system.
l Among those with deep-infiltrating endometriosis, 50% would have a second therapeutic laparoscopy.
l It was assumed that all women only required one type of treatment, with women who had more than
one condition being assumed to need a therapeutic laparoscopy if any one of their conditions required
this treatment.
Quality of life
l Women who dropped out after the baseline assessment, and did not go on to receive testing or
treatment, had the same QoL estimates at 6 months as were measured at baseline.
l For women who received treatment, their QoL changed in response to treatment 4 weeks after
entering the model.
l The impact on QoL of therapeutic laparoscopy was assumed to be the same as for all other treatments.
Data requirements
The data requirements for the economic evaluation were fulfilled through the use of the patient-level data
collected as part of the MEDAL study.
Prevalence of the structural causes of chronic pelvic pain
Only women who were found to have a structural cause of CPP were considered to require treatment,
with the remaining women assumed to be negative for structural causes. In this model, the treatments for
structural causes of CPP were presented in two groups:
1. therapeutic laparoscopy – for women who required a therapeutic laparoscopy to resolve their structural
cause of CPP
2. other treatment – for women who had a structural cause of CPP, but did not require a therapeutic
laparoscopy, which, in this case, are women with fibroids and adenomyosis.
As shown in Table 14, data collected during the MEDAL study found that some women had more than
one structural cause. In this case, if any of the women’s structural causes were considered to be an
appropriate justification for a therapeutic laparoscopy, they would be incorporated into this group
(see Model assumptions). The prevalence of structural causes by treatment group is shown in Table 15.
Test accuracy
The test accuracy of diagnostic laparoscopy and MRI was based on the sensitivity and specificity for the
detection of structural causes that required either a therapeutic laparoscopy or other treatment, and were
informed by data collected during the MEDAL study.
ECONOMIC EVALUATION
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TABLE 15 Prevalence of structural causes stratified by treatment group
Prevalence category Number of cases (% of total) Notes
No structural cause 164 (57.14)
Structural cause requires therapeutic laparoscopya 112 (39.02)
Structural cause requires other treatmentb 11 (3.83)
Total 287
a Includes women with superficial peritoneal endometriosis, deep-infiltrating endometriosis (who may require a second
therapeutic laparoscopy), endometrioma of the ovary, adhesions and ovarian cysts.
b Includes women with fibroids or adenomyosis (no women with both conditions were seen in this study).
Percentages do not add up to 100% as a result of rounding.
TABLE 14 Disease status of the women in the MEDAL study by treatment group
Condition
Number
of cases
Prevalence, %
(95% CI) (N= 287)
Treatment
group
None 164 57.1 (51.2 to 62.9) –
Superficial peritoneal endometriosis only 46 16.0 (12.0 to 20.8) TL
Deep-infiltrating endometriosis only 20 7.0 (4.3 to 10.6) TL
Adhesions only 15 5.2 (3.0 to 8.5) TL
Superficial peritoneal endometriosis and deep-infiltrating
endometriosis
10 3.5 (1.7 to 6.3) TL
Adenomyosis only 8 2.8 (1.2 to 5.4) Other
Superficial peritoneal endometriosis and adhesions 5 1.7 (0.6 to 4.0) TL
Superficial peritoneal endometriosis, deep-infiltrating endometriosis
and endometrioma of the ovary
4 1.4 (0.4 to 3.5) TL
Fibroids only 3 1.1 (0.2 to 3.0) Other
Deep-infiltrating endometriosis and endometrioma of the ovary 2 0.7 (0.1 to 2.5) TL
Endometrioma of the ovary only 2 0.7 (0.1 to 2.5) TL
Superficial peritoneal endometriosis and endometrioma of the ovary 2 0.7 (0.1 to 2.5) TL
Deep-infiltrating endometriosis and adhesions 1 0.4 (0.01 to 1.9) TL
Deep-infiltrating endometriosis, superficial peritoneal endometriosis
and adhesions
1 0.4 (0.01 to 1.9) Tl
Deep-infiltrating endometriosis, superficial peritoneal endometriosis,
adhesions and fibroids
1 0.4 (0.01 to 1.9) TL
Deep-infiltrating endometriosis, superficial peritoneal endometriosis,
endometrioma of the ovary, adhesions and adenomyosis
1 0.4 (0.01 to 1.9) TL
Ovarian cysts and adenomyosis 1 0.4 (0.01 to 1.9) TL
Superficial peritoneal endometriosis and adenomyosis 1 0.4 (0.01 to 1.9) TL
Other, other treatment; TL, therapeutic laparoscopy.
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The test accuracy of MRI and diagnostic laparoscopy, respectively, was explored through the use of ROC
curves for structural causes that required a therapeutic laparoscopy, and for those that required other
treatment (Figure 11). The ROC curve was created by plotting the true-positive rate (true-positive rate or
sensitivity) against the false-positive rate (false-positive rate or 1 – specificity) at various threshold settings.
In our analysis, we refer to a low cut-off point as one that sets a high sensitivity and low specificity
(more positive tests), and a high cut-off point as one that sets a low sensitivity and high specificity
(more negative tests).
Calculation of test-accuracy parameters
In order to incorporate the impact of the test results on patient outcomes into the model, it was necessary
to combine the prevalence of CPP with the sensitivity and specificity of the tests.
A patient in the model could be in one of three disease states:
1. patient has a structural cause that requires therapeutic laparoscopy
2. patient has a structural cause that requires other treatment
3. patient tests negative for any structural cause of CPP.
0
20
40
60
80
100
020406080100
Se
n
si
ti
vi
ty
Specificity
(a)
0
20
40
60
80
100
020406080100
Se
n
si
ti
vi
ty
Specificity
(b)
FIGURE 11 Receiver operating characteristic curves for laparoscopic and MRI diagnoses. (a) Diagnostic laparoscopy
for structural causes of CPP that required treatment using a therapeutic laparoscopy; (b) diagnostic laparoscopy for
structural causes of CPP that required other treatment (not therapeutic laparoscopy); (c) MRI scan for structural
causes of CPP that required treatment using a therapeutic laparoscopy; and (d) MRI scan for structural causes of
CPP that required other treatment (not therapeutic laparoscopy). (continued )
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The prevalence of disease based on these groupings was combined with the test-accuracy characteristics of
the tests through the following equations to give the proportion of women who test true or false positive
or negative for a structural cause of CPP:
TP(TL) = Sens(TL)P(TL), (1)
FN(TL) = ½1−Sens(TL)P(TL), (2)
TP(OT) = Sens(OT)P(OT), (3)
FN(OT) = ½1−Sens(OT)P(OT), (4)
TN = ½1−P(TL)−P(OT)Spec(TL)Spec(OT), (5)
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FIGURE 11 Receiver operating characteristic curves for laparoscopic and MRI diagnoses. (a) Diagnostic laparoscopy
for structural causes of CPP that required treatment using a therapeutic laparoscopy; (b) diagnostic laparoscopy for
structural causes of CPP that required other treatment (not therapeutic laparoscopy); (c) MRI scan for structural
causes of CPP that required treatment using a therapeutic laparoscopy; and (d) MRI scan for structural causes of
CPP that required other treatment (not therapeutic laparoscopy).
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FP(TL) = 1−P(TL)−P(OT)ð Þ−TNð Þ(Spec(OT)/(Spec(OT) + Spec(TL)), (6)
FP(OT) = ð1−P(TL)−P(OT))−TNð ÞSpec(TL)/(Spec(OT) + Spec(TL)ð Þ, (7)
in which Sens is the sensitivity of the test, Spec is the specificity of the test, TP is a true-positive test result,
FP is false positive, TN is true negative, FN is false negative and P is the prevalence of women with a
structural cause subdivided into those women who require a therapeutic laparoscopy (TL) and those who
require other treatment (OT).
Further model parameters
Parameters describing the uptake of MRI and laparoscopy are shown in Table 16 below. These were
informed by the data collection conducted in the MEDAL study. As described in Model assumptions, 50%
of women with deep-infiltrating endometriosis were assumed to receive two therapeutic laparoscopies.
This was incorporated into the analysis for the purpose of calculating costs, but had no influence on
patient outcomes, and the impact of this assumption was examined during the sensitivity analysis
(see Sensitivity analyses).
Cost and resource data
All costs used in this evaluation are in UK pounds sterling (at the 2013 value). NHS Reference Costs
2013–1487 were used to attribute costs to the resource use. The Unit Costs of Health and Social Care 201488
from the Personal Social Services Research Unit were used to obtain the costs for staff time. The resource
costs are shown in Table 17.
Outcomes
The primary outcome of this economic evaluation was the quality-adjusted life-year (QALY). In addition, the
outcomes of cost per patient correctly diagnosed, and cost per patient correctly treated, were examined.
The QALY outcome measure was informed by QoL estimates obtained from the MEDAL study, through the
EQ-5D-3L questionnaire, which was administered at baseline and 6 months post laparoscopy. This was not
a randomised controlled trial in which women followed different patient pathways, and so it was not
possible to obtain the QoL values for all the different patient pathways. Instead, the baseline values were
used to inform the impact of a patient either having a structural cause of CPP or not having one, and then
6-month values were used to inform the impact on QoL of having a treatment with or without a cause of
CPP. As no information was collected describing the impact of treatment on fibrosis or adenomyosis at
6 months, only the impact of therapeutic laparoscopy on QoL was considered. This QoL effect was
assumed to be the same as the impact of treatment for fibrosis or adenomyosis (see Model assumptions).
The QoL values used in this study are shown in Table 18.
TABLE 16 Parameters used in the decision model
Parameters Value References Notes
Proportion of eligible women who received
a laparoscopy when offered
288/309 Data Intraoperative form missing for one patient,
and so was not included in the final analysis
Proportion of eligible women who received
a MRI scan when offered
291/329 Data Intraoperative form missing for four women,
and so were not included in the final analysis
Proportion of women who had a
therapeutic laparoscopy during the same
procedure as a diagnostic laparoscopy
92/112 Data Remainder of women had therapeutic
laparoscopy during a subsequent procedure
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Analysis
This model-based economic evaluation takes the form of a cost–utility analysis based on the primary
outcome of cost per QALY. The secondary outcomes of the cost per patient correctly diagnosed and cost
per patient appropriately treated were also considered as part of the wider cost-effectiveness analyses.
The perspective of the analysis is the health-care provider perspective (the UK NHS) in a secondary care
(hospital) setting. Given the 6-month time horizon, no discounting was applied. The results in this study
are described using the incremental cost-effectiveness ratio (ICER); this is defined as the difference
between the costs of the two strategies divided by the difference in their outcomes.
In this analysis, for each of the strategies, MRI and laparoscopy, the cut-off value for sensitivity and
specificity is treated as a decision variable, rather than an endogenous characteristic of each test. Given
that there are 12 cut-off points for each ROC curve, this leads to 24 alternative strategies for MRI and
laparoscopy, and, with the no-testing strategy, 25 alternative strategies were considered here.
TABLE 17 Breakdown of the costs used in the economic analysis
Item Code Cost (£) Reference Notes
Consultant/hour Consultant medical (with qualification
costs)
140 Unit Costs of
Health and Social
Care 201488
Nurse/hour Nurse, day ward [includes staff nurse,
registered nurse, registered practitioner)/
hour of patient contact (with qualification
costs)]
100
Ultrasound RA24Z ultrasound scan, ≥ 20 minutes
(diagnostic imaging)
59 NHS Reference
Costs 2013–1487
Baseline
examination
Twenty minutes of consultation time
with a consultant and a nurse, followed
by 20 minutes of physical examination
by a consultant, and then two-thirds of
women received an ultrasound scan
166 Assume mean is equal to
standard error for nurse
and consultant time89
Diagnostic
laparoscopy
MA10Z minor laparoscopic or
endoscopic procedure, upper genital
tract procedure (day case)
1217 NHS Reference
Costs 2013–1487
Therapeutic laparoscopy
assumed to be 10% more
expensive than diagnostic
laparoscopy (see
assumptions)
MRI RA03Z MRI scan, one area, pre and post
contrast (diagnostic imaging)
203
Hysterectomy MA07G major open upper genital tract
procedures with a CC score of 0–2
3299 Applied to 50% of those
women with adenomyosis
Implantation of
an intrauterine
device
MA35Z implementation of an
intrauterine device
311 Applied to 50% of those
women with adenomyosis
Fibroids MB09C non-malignant gynaecological
disorders with interventions with a CC
score of 0–2
2520
CC, complications and comorbidities.
All costs are in pounds sterling (£); the cost year is 2013/14.
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Sensitivity analyses
A range of one-way sensitivity analyses were undertaken to gain further insights into the impact of
reasonable changes to key parameters in the model, as follows:
1. To examine the impact of the 6-month time horizon on the model results, this was extended beyond
the period of data collection up to 3 years. However, as a result of a lack of data being collected in
this study beyond 6 months, this required two assumptions to be made. The first was that the QoL
informed by data at 6 months was constant up to the time horizon under consideration, and the
second was that no costs were incurred beyond the 6 months.
2. To examine the impact of changing the prevalence of structural causes among women with CPP in this
model, this was varied between 0% and 100%. However, when applying the sensitivity analysis, it was
assumed that the ratio of positive women in the therapeutic laparoscopy group to the other treatment
group remained the same, as informed by the MEDAL study data.
3. To examine the impact of the assumption that 50% of women with deep-infiltrating endometriosis
required two therapeutic laparoscopies, this value was varied between 0% and 100%.
4. To examine the impact of the assumption that 50% of women with adenomyosis had a hysterectomy
and 50% had a levonorgestrel-releasing intrauterine system, these values were varied from 0% to
100% (always adding up to 100%).
In order to incorporate the uncertainty that is inherent in many of the parameters in this analysis,
a probabilistic sensitivity analysis (PSA) was undertaken, with each parameter value being assigned a
distribution and the model being run 10,000 times, sampling on each occasion from these distributions.
The distributions applied to the parameters for the PSA are shown in Appendix 3.
TABLE 18 Quality-of-life values used to inform the QALY outcome
QoL estimate
Time point, EQ-5D-3L mean score
(SD, n)
Application in the modelBaseline 6 months
Have a cause of CPP that requires
therapeutic laparoscopya
0.56 (0.32, 112) QoL of women with a cause of CPP at
baseline, and those who tested FN and,
thus, were not treated
Do not have a cause of CPPb 0.53 (0.32, 151) QoL of women who tested negative for a
cause of CPP at baseline
Do not have any cause of CPP and
receive therapeutic laparoscopyc
0.55 (0.35, 53) QoL of negative women who tested FP
and received unnecessary treatment
Do not have any cause of CPP and do
not receive therapeutic laparoscopyd
0.69 (0.26, 71) QoL of negative women at 6 months
who tested TN and did not receive
treatment
Have cause of CPP that requires
therapeutic laparoscopy and receives
therapeutic laparoscopye
0.74 (0.28, 68) QoL of women who tested TP and
received treatment
FN, false negative; FP, false positive; TN, true negative.
a Twenty-eight values missing from 6 months post laparoscopy.
b Five values missing from baseline.
c Eight values missing from 6 months post laparoscopy.
d Twenty-three values missing from 6 months post laparoscopy.
e Twenty-four values missing from 6 months post laparoscopy.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
Results
This section starts by examining the cost-effectiveness of MRI, laparoscopy, and no testing, whereby the
different cut-off values to inform the sensitivity and specificity for each test was treated as a separate
strategy. At baseline, a 6-month time horizon was utilised.
Quality-adjusted life-year outcome
Using the outcome of the QALYs, the cost-effectiveness of MRI and laparoscopy across varying cut-off
points is shown in Table 19.
As shown in Table 20, the baseline results for strategies on the cost-effectiveness frontier, using the
outcome of the QALY for most scenarios and excluding the scenarios for the more extreme cut-off
TABLE 19 Baseline deterministic cost-effectiveness results for MRI and laparoscopy at various cut-off points using
the QALY outcome and a 6-month time horizon
Strategy and cut-off pointa Cost (£) QALY gain
MRI – 2 1856 0.3077
MRI – 1 1908 0.3082
MRI – 0 2097 0.3083
Laparoscopy – 0 2231 0.3084
MRI – 10 538 0.3094
No testing 166 0.3095
MRI – 11 497 0.3095
Laparoscopy – 11 1387 0.3095
MRI – 3 1691 0.3097
MRI – 4 1397 0.3100
MRI – 9 623 0.3103
MRI – 8 729 0.3109
MRI – 5 1171 0.3121
Laparoscopy – 1 2017 0.3134
MRI – 7 862 0.3137
MRI – 6 1002 0.3140
Laparoscopy – 10 1481 0.3140
Laparoscopy – 2 1973 0.3166
Laparoscopy – 9 1593 0.3176
Laparoscopy – 3 1904 0.3188
Laparoscopy – 8 1664 0.3200
Laparoscopy – 4 1873 0.3212
Laparoscopy – 5 1839 0.3215
Laparoscopy – 7 1747 0.3227
Laparoscopy – 6 1793 0.3235
a Cut-off points are based on the data points in Figure 11, which were obtained from questionnaires. There are 12 data
points in these graphs, which matches the number of cut-off points.
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points, shows that laparoscopy is more effective than MRI in terms of QALYs gained. For both MRI and
laparoscopy, for some of the highest and lowest cut-off values that appear at the extreme ends on the
ROC curve, in terms of QALYs gained, these are no better than no testing, and, in some cases, are even
worse than no testing. This can be explained, as, for some of these strategies, women are given expensive
unnecessary treatment as a result of false-negative test results. Finally, it is noted that for most scenarios,
excluding the scenarios for the more extreme cut-off points, laparoscopy is more effective than MRI in
terms of QALYs gained. The cost-effectiveness frontier for the results in Table 20 is shown in Figure 12.
As can be seen in Figure 12, all the strategies were either dominated (less effective and more costly) or
subject to extended dominance (another strategy provides more units of benefit at a lower cost per unit
of benefit), except for no testing and laparoscopy, at a cut-off value of 6, which therefore lies on the
cost-effectiveness frontier.
As shown in Table 20, for a 6-month time horizon, using the outcome of the QALY, laparoscopy (with a
cut-off value of 6) is more expensive (£1793 vs. £166) and more effective (0.3235 vs. 0.3095) than no
testing. In addition, the ICER for laparoscopy (with a cut-off value of 6) compared with no testing is
£116,618, which means that one extra QALY gained from laparoscopy (with a cut-off value of 6) will cost
£116,618 compared with no testing.
Correctly diagnosed outcome
Using the outcome measure of a correct diagnosis, the cost-effectiveness results for MRI and laparoscopy
at various cut-off points, for a 6-month time horizon, are shown in Table 21.
As shown in Table 21, for the outcome of correctly diagnosed, the strategies at the extreme ends of the ROC
curve were the least effective, with a few exceptions. The most effective strategies were the laparoscopy
strategies around the mid-point of the ROC curve, that is, the cut-off values 4–9. The cost-effectiveness
frontier for the results in Table 21 is shown in Figure 13.
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FIGURE 12 Cost-effectiveness frontier for the baseline strategies, using the QALY outcome and the 6-month
time horizon.
TABLE 20 Baseline deterministic results for strategies on the cost-effectiveness frontier using the QALY outcome
Strategy Cost (£)
Incremental
cost (£)
QALYs
gained
Incremental
effectiveness
ICER
(cost/QALY), £
No testing 166 0.3095
Laparoscopy (cut-off value of 6) 1793 1627 0.3235 0.014 116,618
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TABLE 21 Baseline deterministic cost-effectiveness results for MRI and laparoscopy at various cut-off points, using
the correctly diagnosed outcome and a 6-month time horizon
Strategy and cut-off pointa Cost (£) Correctly diagnosed
No testing 166 0.0000
Laparoscopy – 0 2231 0.3994
MRI – 0 2097 0.4286
MRI – 2 1856 0.4303
MRI – 1 1908 0.4310
MRI – 3 1691 0.4770
Laparoscopy – 1 2017 0.4897
MRI – 4 1397 0.5051
Laparoscopy – 11 1387 0.5326
Laparoscopy – 2 1973 0.5447
MRI – 5 1171 0.5547
MRI – 10 541 0.5654
MRI – 8 729 0.5709
MRI – 11 497 0.5714
MRI – 9 623 0.5717
Laparoscopy – 10 1498 0.5801
Laparoscopy – 3 1904 0.5838
MRI – 6 1002 0.5956
MRI – 7 862 0.6022
Laparoscopy – 9 1593 0.6195
Laparoscopy – 4 1873 0.6255
Laparoscopy – 5 1839 0.6369
Laparoscopy – 8 1664 0.6421
Laparoscopy – 7 1747 0.6679
Laparoscopy – 6 1793 0.6733
a Cut-off points are based on the data points in Figure 11, which were obtained from questionnaires. There are 12 data
points in these graphs, which matches the number of cut-off points.
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FIGURE 13 Cost-effectiveness frontier for baseline strategies, using the correctly diagnosed outcome and a
6-month time horizon.
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As can be seen in Figure 13, all the strategies were either dominated or subject to extended dominance,
except for the four strategies on the cost-effectiveness frontier, these being no testing, MRI (cut-off value
of 11), MRI (cut-off value of 6) and laparoscopy (cut-off value of 6).
As shown in Table 22, for a 6-month time horizon and using the outcome of correctly diagnosed, MRI
(cut-off value of 11) was more expensive and more effective than no testing. MRI (cut-off value of 7) was
more expensive and more effective than MRI (cut-off value of 11), and laparoscopy (cut-off value of 6) was
more expensive and more effective than MRI (cut-off value of 7). In the case of the comparison between
laparoscopy (cut-off value of 6) and MRI (cut-off value of 7), the ICER was £13,092, which means that it
would cost £13,092 for one extra correct diagnosis for laparoscopy (cut-off value of 6) compared with MRI
(cut-off value of 7).
Correctly treated outcome
Using the outcome measure of a patient being positive for a structural cause of CPP and receiving the
correct treatment, the model results for MRI and laparoscopy at various cut-off points, for a 6-month time
horizon, are shown in Table 23.
Table 23 shows that the least effective scenarios were the MRI strategies with low cut-off points,
that is, those with high sensitivity and low specificity. The most effective scenarios were the laparoscopy
scenarios for the cut-off values 3–10. The cost-effectiveness frontier for the results in Table 23 is shown
in Figure 14.
As can be seen in Figure 14, all the strategies were either dominated or subject to extended dominance,
except for the three strategies on the cost-effectiveness frontier, which were no testing, MRI (cut-off value
of 11), and laparoscopy (cut-off value of 6).
As shown in Table 24, for a 6-month time horizon, using the outcome of a women being correctly treated
with MRI (cut-off value of 11) was more expensive (£497 vs. £166) and more effective (0.5714 vs. 0) than
no testing, and the ICER for MRI (cut-off value of 11) compared with no testing was £579, which means
that one extra patient correctly treated with MRI (cut-off value of 11) would cost £579 compared with no
testing. Likewise, laparoscopy (cut-off value of 6) was more expensive (£1793 vs £497) and more effective
(0.7121 vs. 0.5714) than MRI (cut-off value of 11) with an ICER of £9211, meaning that one extra woman
correctly treated with laparoscopy (cut-off value of 6) will cost £9211 compared with MRI (cut-off value
of 11).
TABLE 22 Baseline deterministic results for strategies on the cost-effectiveness frontier, using the correctly
diagnosed outcome
Strategy Cost (£)
Incremental
cost (£)
Correctly
diagnosed
Incremental
effectiveness
ICER (cost/correctly
diagnosed), £
No testing 166 0
MRI (cut-off value of 11) 497 331 0.5714 0.5714 579
MRI (cut-off value of 7) 862 365 0.6022 0.0308 11,864
Laparoscopy (cut-off value of 6) 1793 1627 0.6733 0.0711 13,092
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FIGURE 14 Cost-effectiveness frontier for baseline strategies, using the correctly treated outcome with a 6-month
time horizon.
TABLE 23 Baseline deterministic cost-effectiveness results for MRI and laparoscopy at various cut-off points, using
the correctly treated outcome and a 6-month time horizon
Strategy and cut-off valuea Cost (£) Correctly treated
No testing 166 0.0000
MRI – 0 2097 0.4286
MRI – 2 1856 0.4303
MRI – 1 1908 0.4310
Laparoscopy – 0 2231 0.4383
MRI – 3 1691 0.4770
MRI – 4 1397 0.5051
Laparoscopy – 1 2017 0.5285
MRI – 5 1171 0.5547
MRI – 10 541 0.5654
MRI – 8 729 0.5709
MRI – 11 497 0.5714
Laparoscopy – 11 1387 0.5714
MRI – 9 623 0.5717
Laparoscopy – 2 1973 0.5835
MRI – 6 1002 0.5956
MRI – 7 862 0.6022
Laparoscopy – 10 1498 0.6189
Laparoscopy – 3 1904 0.6226
Laparoscopy – 9 1593 0.6583
Laparoscopy – 4 1873 0.6643
Laparoscopy – 5 1839 0.6757
Laparoscopy – 8 1664 0.6810
Laparoscopy – 7 1747 0.7068
Laparoscopy – 6 1793 0.7121
a Cut-off points are based on the data points in Figure 11, which were obtained from questionnaires. There are 12 data
points in these graphs, which matches the number of cut-off points.
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Sensitivity analysis
Time horizon
The baseline analysis has a time horizon of 6 months. The impact of extending the time horizon up to
3 years for the outcome of the QALY on model results is shown in Table 25.
The results when varying the time horizon are shown in Table 25. In each case, only the strategies that lie
on the cost-effectiveness plane are shown (dominated and subject to extended dominance scenarios not
shown). It can be seen that, as the time horizon of the analysis is increased, laparoscopy (cut-off value of 6)
becomes more cost-effective than no testing. However, it is noted that, although the effectiveness of the
interventions increases over time, as a result of the model assumptions, the costs remain the same.
Prevalence
The impact of varying the overall prevalence of structural causes among women with CPP was examined,
with the results shown in Table 26. Note that only the results for the scenarios that lie on the cost-effectiveness
frontier are described.
TABLE 25 Model results for the QALY outcome with variations in the time horizon of the analysis strategy
Time horizon and strategy Cost (£)
Incremental
cost (£)
QALYs
gained
Incremental
effectiveness ICER (cost/QALY), £
6-month time horizon
No testing 166 0.3095
Laparoscopy (cut-off value of 6) 1793 1627 0.3235 0.0140 116,618
1-year time horizon
No testing 166 0.6267
Laparoscopy (cut-off value of 6) 1793 1627 0.6574 0.0307 53,000
2-year time horizon
No testing 166 1.2610
Laparoscopy (cut-off value of 6) 1793 1627 1.3251 0.0641 25,384
3-year time horizon
No testing 166 1.8952
Laparoscopy (cut-off value of 6) 1793 1627 1.9929 0.0977 16,654
TABLE 24 Baseline deterministic results for strategies on the cost-effectiveness frontier, using the correctly treated
strategy outcome
Strategy Cost (£)
Incremental
cost (£)
Correctly
diagnosed
Incremental
effectiveness
ICER (cost/correctly
treated), £
No testing 166 0
MRI (cut-off value of 11) 497 331 0.5714 0.5714 579
Laparoscopy (cut-off value of 6) 1793 1296 0.7121 0.1407 9211
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Table 26 shows the model results with variations in the prevalence of a structural cause of CPP. At low
prevalence rates (0–20%), no testing is cheaper and more effective than all other strategies. As the
prevalence increases, laparoscopy (cut-off value of 6) becomes increasingly cost-effective up to 60%, and
then laparoscopy (cut-off value of 4) is preferred for prevalences of 70–80%. At the highest prevalence
rates, MRI with a low cut-off value becomes the preferred option. This can be explained through the fact
that, with a high prevalence rate, it is better to offer a cheap test that has a high sensitivity and low
specificity, as there will be few false-positive test results.
Deep-infiltrating endometriosis
It was assumed that at baseline 50% of women with deep-infiltrating endometriosis required a second
therapeutic laparoscopy. The results in Table 27 show the impact of varying this assumption from 0%
to 100%.
TABLE 26 Model results using variations in the prevalence of a structural cause of CPP
Prevalence
Strategy (with
cut-off value) Cost (£)
Incremental
cost (£)
QALY
gain
Incremental
QALY ICER (cost/QALY), £
0% No testing 166 0.3317 Dominates
10% No testing 166 0.3264 Dominates
20% No testing 166 0.3214 Dominates
30% No testing 166 0.3162
30% Laparoscopy – 7 1730 1564 0.3198 0.0036 430,292
40% No testing 166 0.3110
40% Laparoscopy – 6 1788 1622 0.3227 0.0117 138,407
Baseline (42.86%) No testing 166 0.3095
Baseline (42.86%) Laparoscopy – 6 1793 1627 0.3235 0.0140 116,618
50% No testing 166 0.3058
50% Laparoscopy – 6 1805 1639 0.3256 0.0197 83,032
60% No testing 166 0.3007
60% Laparoscopy – 6 1820 1654 0.3285 0.0278 59,389
70% No testing 166 0.2955
70% Laparoscopy – 6 1836 1670 0.3315 0.0360 46,398
70% Laparoscopy – 4 1896 60 0.3327 0.0012 48,842
80% No testing 166 0.2903
80% Laparoscopy – 4 1905 1739 0.3369 0.0467 37,255
80% MRI – 0 2061 156 0.3388 0.0018 85,124
90% No testing 166 0.2852
90% MRI – 1 1959 1793 0.3445 0.0593 30,248
90% MRI – 0 2051 91 0.3467 0.0022 40,899
100% No testing 166 0.2800
100% MRI – 1 1970 1804 0.3523 0.0723 24,966
100% MRI – 0 2042 72 0.3550 0.0027 26,169
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As shown in Table 26, varying the parameter describing the percentage of women with deep-infiltrating
endometriosis who required two therapeutic laparoscopies had very little impact on the ICER values, and
did not impact on the conclusions drawn from the model. All the ICER values lie close to the baseline
ICER of £116,618 and remain above the £20,000–30,000 acceptance threshold for the cost/QALYs,
as recommended by the National Institute for Health and Care Excellence (NICE).90
Hysterectomy for adenomyosis
It was assumed at baseline that 50% of women with adenomyosis are treated with a hysterectomy.
The results in Table 28 show the impact of varying this assumption from 0% to 100%.
As shown in Table 28, varying the parameter describing the percentage of women with adenomyosis
who are treated with hysterectomy had very little impact on the ICER values, and did not impact on the
conclusions drawn from the model. All the ICER values lie close to the baseline ICER of £116,618, and
remain above the £20,000–30,000 acceptance threshold for the cost/QALYs, as recommended by NICE.
TABLE 27 Model results with a variation in the proportion of women with deep-infiltrating endometriosis who
required a second therapeutic laparoscopy
Proportion of women with deep-infiltrating
endometriosis who required two
therapeutic laparoscopies Cost (£)
Incremental
cost (£)
QALY
gain
Incremental
QALY
ICER
(cost/QALY), £
0%
No testing 166 0.3095
Laparoscopy – 6 1730 1564 0.3235 0.014 112,109
Baseline
No testing 166 0.3095
Laparoscopy – 6 1793 1627 0.3235 0.014 116,618
100%
No testing 166 0.3095
Laparoscopy – 6 1856 1690 0.3235 0.014 121,126
TABLE 28 Model results with variation in the proportion of women with adenomyosis who were treated with
a hysterectomy
Proportion of women with ademomysis
who were treated with a hysterectomy Cost (£)
Incremental
cost (£)
QALY
gain
Incremental
QALY
ICER
(cost/QALY), £
0%
No testing 166 0.3095
Laparoscopy – 6 1682 1516 0.3235 0.014 108,624
Baseline
No testing 166 0.3095
Laparoscopy – 6 1793 1627 0.3235 0.014 116,618
100%
No testing 166 0.3095
Laparoscopy – 6 1905 1739 0.3235 0.014 124,612
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Probabilistic sensitivity analysis
The results for the PSA for 10,000 model runs are shown in the cost-effectiveness acceptability curves in
Figure 15, and those results for no testing and laparoscopy (cut-off value of 6) are shown in Figure 16. These
two strategies were chosen because they appear on the cost-effectiveness frontier at baseline. From Figure 15,
no testing is always the most likely strategy to be cost-effective across willingness-to pay-values for the QALY
from £0 to £200,000. In Figure 16, it can be seen that no testing is more likely to be cost-effective up to a
willingness to pay for a QALY of approximately £150,000, at which point laparoscopy (cut-off value of 6) is
more likely to be cost-effective.
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FIGURE 16 Cost-effectiveness acceptability curve showing the uncertainty in the difference between costs and
effectiveness (QALYs gained) for no testing and laparoscopy (cut-off 6) for 10,000 model runs using a 6-month
time horizon.
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 50 100 150 200
Pr
o
b
ab
ili
ty
 (
st
ra
te
g
y 
co
st
-e
ff
ec
ti
ve
)
Willingness to pay (£000/QALY)
No testing
Laparoscopy: cut-off value of 6
Laparoscopy: cut-off value of 7
MRI: cut-off value of 0
MRI: cut-off value of 1
FIGURE 15 Cost-effectiveness acceptability curve showing the results of the PSA for a 6-month time horizon, for
the strategies likely to be cost-effective across a range of willingness-to-pay thresholds for the QALY.
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Chapter 5 Discussion
Principal findings
The diagnostic study demonstrated that, compared with the reference standard diagnosis verified at
laparoscopy, MRI had high specificity but poor sensitivity for observing deep-infiltrating endometriosis (3%),
endometrioma (33%), adhesions (19%) and ovarian cysts (20%). Sensitivity was higher for detecting these
conditions as a cause of pelvic pain as categorised by the EIP, but not high enough to be useful. MRI correctly
identified 56% of those women judged to have idiopathic CPP, but missed 46% of those women considered
to have a gynaecological structural cause of CPP.
Laparoscopy was significantly more accurate than MRI in diagnosing idiopathic CPP (p < 0.0001), superficial
peritoneal endometriosis (p < 0.0001), deep-infiltrating endometriosis (p < 0.0001) and endometrioma of the
ovary (p = 0.02) as the cause of pelvic pain. The accuracy of laparoscopy appeared to be able to rule in these
diagnoses. Laparoscopy was not able to make accurate diagnoses that adhesions were the cause of pelvic
pain, nor was it able to diagnose adenomyosis.
Using MRI to identify those who require therapeutic laparoscopy would lead to 369 women in a cohort
of 1000 receiving laparoscopy unnecessarily, and 136 women who required laparoscopy not receiving it.
A strategy of all women receiving laparoscopy would lead to 557 women receiving unnecessary laparoscopic
treatment.
Feeding these diagnostic performance data into a decision-analytic model, using a 6-month time horizon
and taking the test cut-off value to inform the sensitivity and specificity values as a decision variable, it was
found that diagnostic laparoscopy (with a cut-off value of 6) has an ICER value of £116,223 (cost/QALY)
compared with a no-testing scenario, in which women only have a baseline examination and are then left
untreated. This means that one extra QALY gained from the diagnostic laparoscopy will cost an average of
£116,618 compared with no testing. This ICER is above the NICE acceptance threshold of £20,000–30,000
for the QALY. However, this value is based on a short time horizon (only 6 months) and strong assumptions,
particularly regarding QALY gain in women treated with different strategies which were not actually
observed in the study, which must be considered alongside these limitations, and does not provide strong
enough evidence to inform clinical care.
Notably, all other scenarios, including all of the MRI scenarios across all cut-off values, were found to be
either dominated (more costly and less effective) or subject to extended dominance (another strategy
provides more units of benefit at a lower cost per unit of benefit). This means that MRI is not cost-effective
in this setting.
As part of an extensive sensitivity analysis, the time horizon was extended to 3 years. Under these
circumstances, the ICER for laparoscopy (with a cut-off value of 6) was £16,654 (cost/QALY) compared
with the no-testing scenario, which would not be considered cost-effective. However, it is noted that
extending the time horizon beyond the data collection period of 6 months does require further strong
assumptions to be made. Nevertheless, this result does suggest that a time horizon of > 6 months should
be adopted for data collection in this setting in future studies, in order for the impact of these interventions
on patient QoL to be fully evaluated.
The ICER values for the outcome of cost per correct diagnosis were £579 for MRI (with a cut-off value of 11)
versus no testing, £11,864 for MRI (with a cut-off value of 7) versus MRI (with a cut-off value of 11) and
£13,092 for laparoscopy (with a cut-off value of 6) versus MRI (with a cut-off value of 7). In addition, the
costs per patient correctly treated were £579 for MRI (with a cut-off value of 11) versus no testing, and
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£9211 for laparoscopy (with a cut-off value of 6) versus MRI (with a cut-off value of 11). Although it is
difficult to draw conclusions as to which strategy should be preferred based on these outcomes, as there
is no acceptable threshold for either outcome, it is notable that laparoscopy (with a cut-off value of 6)
continues to be the most cost-effective strategy for each.
Strengths and weaknesses of the diagnostic study
The MEDAL study examined the diagnostic value and cost-effectiveness of MRI placed before laparoscopy in
a care pathway for women presenting with CPP (incorporating several target conditions) in a gynaecology
clinic. If found to be accurate and cost-effective, a strategy involving use of MRI triage to direct laparoscopy
could lead to more selective use of the latter, an invasive, costly test requiring use of general anaesthesia in a
day-case operating theatre. Construction of an appropriate study designed to produce valid, reliable and
generalisable results to guide decision-making proved to be challenging from the outset. The challenges
included, among others, variation in gynaecological practice; multiplicity of target conditions with respect to
cause of CPP; incongruence between observed conditions and attribution of cause to CPP symptoms; a lack
of consensus on radiology standards and reporting of pelvic MRI for benign gynaecological conditions; the
need to blind MRI results to avoid bias in assessment of their value; and a lack of objective reference
standards for the various target conditions.
The MEDAL study was a multicentre study with recruitment from 26 gynaecology outpatient clinics in the
UK. The units represented the spectrum of settings, from busy district general hospitals to specialised tertiary
centres, covering the whole range of existing women’s health referral networks, to hospitals with MRI
facilities. These units served large, socioeconomically and ethnically diverse populations, which served to
maximise the generalisability of the findings. The MEDAL study sought to approach all consecutive eligible
women to obtain a suitably representative sample of women with CPP. The median interval between a MRI
scan and a diagnostic laparoscopy was less than 1 month, making it unlikely that disease progression bias
could influence the results, given the slow and chronic nature of the gynaecological conditions under
consideration. The variation inherent in clinical and radiological practice in this mixture of settings also posed
a challenge with respect to baseline data collection and MRI reporting. Establishing a standard operating
procedure for MRI reporting was a key issue. We established a reporting template for CPP through a survey
of an expert panel of radiologists specialising in gynaecological MRI from across the UK.63 This format would
facilitate the applicability of the findings of our study.
The use of laparoscopy for diagnostic evaluation in CPP was well established as the standard practice in these
settings. Variations existed in the recording of history, gynaecological examination and pelvic ultrasound,
before performing diagnostic laparoscopy. We standardised these during the course of the study using
piloted data collections forms, which all had the input of consumers and experts to ensure sensitivity and
relevance to women and their presenting complaint. These data were necessary for the care provided by the
gynaecologist (who had to be kept blind to the MRI results), but their standardised collection was also
necessary for replicable use by the independent gynaecologist assessing the information gained by MRI and
the EIP, for establishing a reference diagnosis by consensus.
To determine the accuracy of MRI for each condition separately would require a large number of participants
to accommodate the low prevalence of some conditions, such as ovarian cysts. Some pathologies are not
independent of each other and could frequently be concurrently observed; for example, endometriosis can
give rise to adhesions from fibrotic tissue. Furthermore, conditions observed are not always causes of the CPP
symptoms. Therefore, our principal research question was developed to ascertain how MRI could be judiciously
employed in a care pathway to minimise the use of laparoscopy, while maximising the correct identification
of target conditions for treatments (diagnostic study) that improve QoL with the least investigative burden
(decision-analytic cost-effectiveness analysis). Taking this approach, MRI test accuracy for each of the observed
conditions served only as a secondary aim. Understanding the difference between diagnostic accuracy and
diagnostic value in a care pathway is key to the interpretation of our findings.
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To establish whether or not MRI can minimise the use of laparoscopy in a diagnostic pathway, a paired
design was employed whereby both tests were performed in the study cohort. During the conduct of the
study, it was necessary to blind the MRI report so that clinicians providing care remained uninfluenced
by its results in their decision-making, otherwise there was a risk that the assessment of the MRI test
performance in the study may be biased. The MRI test preceded laparoscopy in the study, so its findings
can be interpreted for development of a triage test that can be used to direct only women with specific
conditions towards laparoscopic confirmation or an operative laparoscopic procedure. By providing a MRI
test prior to laparoscopy, any conditions that MRI can identify as a cause of CPP with sufficient accuracy
can be treated medically without laparoscopy, or a therapeutic laparoscopy can be planned without the
need for an initial diagnostic laparoscopy after the findings of the study are known. As it was feasible to
perform MRI and laparoscopy in the same women with CPP in a blinded fashion, so that MRI did not
interfere with laparoscopy, the paired design offered statistical efficiency over a randomised trial
comparing two diagnostic strategies.
The most challenging issue was establishment of a reference diagnosis that attributed cause to the CPP
symptoms. For this, we employed a panel consensus method. The panel reflected the clinical reality in
which several items of information are synthesised to make a treatment decision. In this assessment, the
reference standard in the MEDAL study was kept independent of the MRI test to confirm or refute the
presence or absence of disease beyond reasonable doubt. A judgement was made by the expert panel
about whether or not the conditions observed were a cause of the CPP symptoms without the use of MRI
results, avoiding incorporation bias (except in the evaluation of adenomyosis as a target condition, as other
means for this diagnosis are inadequate).
There is little evidence on how panels should be convened, how information should be presented or what
the best methods for consensus are. We used a standardised approach to minimise variation in delineation
of the reference standard. We established an expert panel of consultant gynaecologists who were not
involved in the care of women recruited in the study. Although non-gynaecological conditions were
considered as potential diagnoses, we did not include experts from other specialities, which may have
contributed to the poor consensus regarding the attribution of pain to non-gynaecological causes. Using an
EIP comprised solely of gynaecologists does, however, produce a diagnosis reflecting the clinical decision
point, as the decision as to whether or not to perform a laparoscopy is made by gynaecologists.
Given the large amount of information to be considered per case, a piloted structured report was produced for
the panel’s consideration. Each panel meeting involved three experts who provided the reference diagnosis for
each case presented based on the structured summary of all the data collected, with the various case report
forms available in their entirety, if required. Each member individually recorded their reference diagnosis. The
meeting chairperson documented the discussion that followed and how agreement was reached through
consensus. Understanding the difference between the presence of a condition and a target condition being the
cause of pain proved to be the main challenge. After running pilot panels, the procedures for the panel meetings
were reviewed and finalised. During the course of the panel assessments, we undertook formal repeatability
testing for inter-rater agreement. We employed the agreement statistics in determining the reliability of the
reference standard for the interpretation of our findings. We found that agreement among experts for the
assignment of gynaecological conditions as causes of CPP was either good or very good, although it was weak
for non-gynaecological conditions.
The MEDAL study has been reported in accordance with the Standards for Reporting of Diagnostic Accuracy
(STARD) statement. Not all items apply to the MEDAL study, as it is not a typical test-accuracy evaluation, but
this statement provides for a minimum requirement to ensure completeness and transparency of reporting.
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Strengths and weaknesses of the economic evaluation
The strength of this model-based analysis is that it has utilised contemporary data informing the test
accuracy of diagnostic laparoscopy and MRI in their application to women with CPP. In addition, these
data have provided information for the model on the impact of successfully testing and treating women
with structural causes of CPP on their QoL. Moreover, as part of this analysis, the cut-off value on the ROC
curve to inform the sensitivity and specificity of each test was treated as a decision variable, meaning that
the most cost-effective test at its optimum cut-off value could be identified.
This analysis has a number of weaknesses that need to be acknowledged. QoL data were collected from
women over a 6-month period only, meaning that a time horizon of only 6 months could be adopted in
the model, unless strong assumptions were made about the QoL and costs incurred beyond 6 months.
During the sensitivity analysis, the time horizon was extended up to 3 years, but this relied on the
assumptions that QoL did not change beyond 6 months and no costs were incurred by either strategy
beyond that time. It is acknowledged that CPP among women is a problem that can often take many
medical consultations to resolve, and so it is likely that the positive benefits of properly diagnosing and
treating a structural cause of CPP will be felt long after the 6-month time horizon considered here.
Given that this model utilised data from a test-accuracy study in which all women received both tests, it
was difficult to tease out the impact of the different test results and the resulting treatment on patient
QoL. This meant that assumptions had to be made regarding how negative test results might affect
women. This is really an unavoidable issue with model-based analyses that examine medical tests, but is
acknowledged here nonetheless.
This economic analysis has considered only the diagnosis and treatment of structural causes of CPP,
and has not included other possible causes of CPP, such as PID. Including more possible causes of CPP
would make the model more cumbersome, and would also require the different treatment and test
characteristics for the new causes to be incorporated into the model. This means that the full patient
benefit of laparoscopy and MRI has not been considered here. Nevertheless, varying the prevalence of
structural causes of CPP was undertaken in the sensitivity analysis presented here, and slightly increasing
the prevalence could be regarded as a proxy for the inclusion of other causes of CPP, and thus this does
help to show how their inclusion might impact on the conclusions drawn from the model.
In this model-based economic evaluation, a decision tree was utilised rather than a Markov model. This
was attributable to the short time horizon and the fact that women acquiring new cases of CPP over time
were not considered in the study. However, it is acknowledged that an individual sampling model could
have been used, whereby the different structural causes of CPP would be described for each patient.
However, given that the testing and treatment pathways for many of the causes of CPP considered in
this study are the same, this approach was considered unnecessary as these pathways could easily be
described using a decision tree.
Public and patient involvement
We have been supported throughout the project by the Pelvic Pain Support Network (PPSN) and, in
particular, its chairperson. Public and patient involvement was crucial in improving the acceptability of the
MEDAL study and promoting recruitment. We engaged with the PPSN chairperson throughout, developing
an appreciation of the apprehension and uncertainty surrounding MRI and laparoscopy among women,
as well as the opinions of clinicians and barriers to accessing MRI that the chairperson had encountered.
This prompted us to provide a study-specific MRI information leaflet to potential participants. We also
believed that it was important to establish a thorough understanding of all aspects of CPP and the
potential underlying conditions, and so we designed the initial patient questionnaire with input from
the PPSN.
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We will engage with the PPSN regarding the dissemination of our findings, providing a plain English
summary of the findings and the uncertainties around the evidence we have discussed here. This will be
distributed via the PPSN website and e-newsletter. Any future research groups taking forward the research
recommendations from this project would benefit from engaging with the PPSN.
Interpretation of the findings
To our knowledge, this is the first study that has examined the diagnostic value and cost-effectiveness of
MRI compared with diagnostic laparoscopy in women with CPP.
The risks of MRI revolve around changing radiofrequencies and magnetic fields, which can theoretically
produce heat that is absorbed by the body tissue; this is not known to produce any side effects.
Conversely, like any surgery, a laparoscopy is not without its risks. It involves day care admission and
general aesthesia. Laparoscopy involves minimal invasion of body tissues, but its complications can include
damage to organs inside the abdomen and wound infections. Therefore, if MRI could minimise the use of
laparoscopy, it could be beneficial to women and health services. Our diagnostic study found that MRI
tests were not accurate for detecting structural gynaecological conditions. Furthermore, it did not add
value over and above baseline history, examination and pelvic ultrasound in verifying the absence of a
cause of CPP symptoms (before performing diagnostic laparoscopy).
With respect to specific gynaecological conditions, MRI was most accurate for endometrioma, adhesions
and fibroids when compared with observations at laparoscopy but, even so, its performance was too
inadequate to be useful. Evaluation of non-gynaecological conditions suffered from poverty of agreement
over verification of the diagnosis by an expert panel, and this limits the useful interpretation of these data.
The health economic analysis found that MRI was never more cost-effective than laparoscopy. Given the
poor accuracy of MRI, this conclusion was expected. Our extended analysis comparing laparoscopy and MRI
with a theoretical no-testing scenario revealed the interesting observation that, at the 6-month follow-up,
a strategy of no laparoscopy or MRI would be the most cost-effective – this finding is likely to be strongly
affected by the short follow-up period (the benefits of successful treatment of CPP are likely to last many
years), and the assumptions made about QoL without treatment (which could not be directly observed in
the study).
Implications for practice
Magnetic resonance imaging was dominated by laparoscopy in the differential diagnosis of women
presenting to gynaecology clinics with CPP. It did not add value to the information, already gained from
history, examination and ultrasound, about idiopathic CPP and various gynaecological conditions before
considering a laparoscopy. The little value it did show for a few conditions, such as endometrioma, could
be obtained only at the cost of undertaking large numbers of scans, and was not cost-effective, as the
small diagnostic gain came tagged with additional costs.
Unanswered questions and further research
The evaluation of subjective tests for differential diagnosis in care pathways targeting various conditions for
treatment requires methodological development. Further data on the individual and joint distributions of
the prevalence of causes of pain would be beneficial. In CPP, the development of diagnostic prediction
models incorporating biomarkers into baseline data may improve the use of diagnostic laparoscopy;
however, research will first be required to determine objective diagnostic criteria for the various target
conditions and valid biomarkers for endometriosis.
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Data sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to available
anonymised data may be granted following review.
Patient data
This work uses data provided by women and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Additional baseline data from the
diagnostic study
TABLE 29 Recruitment by centre
Recruiting centre n (%)
Basildon University Hospital 3 (1)
Birmingham Women’s Hospital 6 (2)
Chelsea and Westminster 24 (8)
Cumberland Infirmary 6 (2)
Dorset County Hospital 3 (1)
Royal Infirmary of Edinburgh 5 (2)
Furness General Hospital 6 (2)
Homerton University Hospital 19 (7)
Liverpool Women’s Hospital 11 (4)
Medway Maritime Hospital 2 (1)
Musgrove Park Hospital 9 (3)
Newham University Hospital 5 (2)
Ninewells Hospital 11 (4)
North Devon District Hospital 7 (2)
Nottingham University Hospital 4 (1)
Royal Hallamshire Hospital 14 (5)
The Royal London Hospital 80 (27)
Royal Preston Hospital 6 (2)
South Tyneside District Hospital 2 (1)
Southend University Hospital 7 (2)
Stafford Hospital 8 (3)
Sunderland Royal Hospital 6 (2)
University Hospital Crosshouse 10 (3)
University Hospital of North Durham 17 (6)
University Hospital of North Staffordshire 16 (6)
Whipps Cross University Hospital 4 (1)
Total 291 (100)
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TABLE 30 Demographic details of participants
Demographic variable Value
Height (cm), mean (SD, n) 1.64 (0.07, 283)
Weight (kg), mean (SD, n) 71.1 (15.3, 274)
Smoking
Smoked > 100 cigarettes during lifetime, n (%, N responses) 117 (40.6, 288)
Current smoker, n (%, N responses) 67 (57.3, 117)
Units of alcohol drunk per week, mean (SD, n) 4.4 (6.5, 275)
Participant affected by special social circumstances, n (%, N responses) 17 (6.0, 283)
TABLE 31 Participant characteristics
Participant characteristics Value
Pain problems
Duration of pain
Duration of pain (years), mean (SD, n) 4.2 (4.8, 287)
Event associated with the onset of pain, n (%, N responses) 136 (48.1, 283)
Change in pain since onset, n (%)
Got a lot worse 155 (53.8)
Got a little worse 57 (19.8)
Not changed 59 (20.5)
Got a little better 12 (4.2)
Got a lot better 2 (0.7)
Do not know 3 (1.0)
Missing 3 (1.0)
Number of days with pelvic pain in previous month
< 1 day per month 4 (1.4)
1 day per month 7 (2.5)
2–3 days per month 47 (16.6)
1 day per week 12 (4.2)
> 1 day per week 100 (35.2)
Every day 114 (40.1)
Missing 7 (2.4)
Location of pain
Severity of pain in each area (0 = no pain, 10=most severe pain imaginable), mean (SD, n)
Left upper back quadrant 0.1 (0.9, 291)
Central upper back 0.2 (1.0, 291)
Right upper back quadrant 0.1 (0.7, 291)
Left lumbar back region 1.2 (2.8, 291)
Central back 1.5 (3.0, 291)
Right lumbar back region 1.2 (2.7, 291)
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TABLE 31 Participant characteristics (continued )
Participant characteristics Value
Left lower back region 1.0 (2.6, 291)
Central lower back 1.3 (3.0, 291)
Right lower back 1.1 (2.8, 291)
Left outer posterior thigh 0.3 (1.5, 291)
Left inner posterior thigh 0.5 (1.8, 291)
Right outer posterior thigh 0.3 (1.5, 291)
Right inner posterior thigh 0.4 (1.7, 291)
Right hypochondriac upper 0.1 (0.9, 291)
Epigastric region 0.1 (0.9, 291)
Left hypochondriac upper 0.1 (0.9, 291)
Right lumbar 1.0 (2.5, 291)
Umbilical region 1.3 (2.9, 291)
Left lumbar 1.0 (2.6, 291)
Right iliac 3.8 (4.1, 291)
Hypogastric/suprapubic 4.5 (4.1, 291)
Left iliac 3.7 (4.1, 291)
Right outer anterior thigh 0.5 (1.8, 291)
Right inner anterior thigh 0.5 (1.9, 291)
Left inner anterior thigh 0.5 (1.7, 291)
Left outer anterior thigh 0.4 (1.7, 291)
Urethral region 0.4 (1.7, 291)
Vulval 0.7 (2.2, 291)
Perianal 0.5 (1.9, 291)
Right inner thigh 0.2 (1.3, 291)
Right buttock 0.1 (0.7, 291)
Left inner thigh 0.2 (1.3, 291)
Left buttock 0.02 (0.4, 291)
Pain just before period (0 = no pain, 10=worst pain imaginable), mean (SD, n) 6.4 (2.6, 264)
Duration in months, mean (SD, n) 24.1 (22.5, 201)
Pain during period (0 = no pain, 10=worst pain imaginable), mean (SD, n) 7.1 (2.8, 266)
Duration in months, mean (SD, n) 25.3 (23.7, 202)
Pain when period is over (0 = no pain, 10=worst pain imaginable), mean (SD, n) 4.8 (2.8, 263)
Duration in months, mean (SD, n) 22.8 (22.0, 184)
Pain mid-cycle (0 = no pain, 10=worst pain imaginable), mean (SD, n) 5.4 (2.9, 263)
Duration in months, mean (SD, n) 23.7 (22.2, 193)
Sexual intercourse in the last month, n (%, N responses) 212 (73.4, 289)
If yes, pain at the point of vaginal penetration (0= no pain, 10=worst pain imaginable), mean (SD, n) 3.6 (3.3, 209)
Duration in months, mean (SD, n) 20.3 (21.4, 114)
If yes, deep pain during intercourse (0 = no pain, 10 =worst pain imaginable), mean (SD, n) 6.0 (3.3, 212)
Duration in months, mean (SD, n) 20.3 (20.7, 146)
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TABLE 31 Participant characteristics (continued )
Participant characteristics Value
If yes, burning vaginal pain during intercourse (0= no pain, 10=worst pain imaginable), mean (SD, n) 2.9 (3.4, 210)
Duration in months, mean (SD, n) 19.8 (18.5, 77)
If yes, pelvic pain lasting hours or days after (0= no pain, 10 =worst pain imaginable), mean (SD, n) 5.1 (3.3, 211)
Duration in months, mean (SD, n) 20.1 (21.1, 134)
Pain when bladder is full (0 = no pain, 10=worst pain imaginable), mean (SD, n) 4.1 (3.3, 286)
Duration in months, mean (SD, n) 18.5 (21.1, 146)
Pain with urination (0 = no pain, 10 =worst pain imaginable), mean (SD, n) 2.1 (2.8, 283)
Duration in months, mean (SD, n) 17.1 (19.7, 95)
Muscle/joint pain in pelvic region (0 = no pain, 10 =worst pain imaginable), mean (SD, n) 4.2 (3.6, 278)
Duration in months, mean (SD, n) 22.5 (22.7, 137)
Pain in pelvis when lifting (0 = no pain, 10 =worst pain imaginable), mean (SD, n) 3.5 (3.4, 282)
Duration in months, mean (SD, n) 21.3 (22.7, 133)
Pain when sitting (0 = no pain, 10=worst pain imaginable), mean (SD, n) 4.0 (3.3, 282)
Duration in months, mean (SD, n) 19.2 (18.1, 147)
Backache (0 = no pain, 10 =worst pain imaginable), mean (SD, n) 5.1 (3.3, 286)
Duration in months, mean (SD, n) 22.7 (24.5, 168)
Migraine headache (0 = no pain, 10=worst pain imaginable), mean (SD, n) 3.4 (3.7, 222)
Duration in months, mean (SD, n) 23.8 (23.5, 93)
Treatments for pain, n (%)
Acupuncture 13 (4.5)
If used, was considered helpful, n (%, N responses) 7 (53.8, 13)
Anti-seizure medications 7 (2.4)
If used, was considered helpful, n (%, N responses) 2 (28.6, 7)
Antidepressants 39 (13.4)
If used, was considered helpful, n (%, N responses) 17 (47.2, 36)
Biofeedback 1 (0.3)
If used, was considered helpful, n (%, N responses) 1 (100, 1)
Botox injection 2 (0.7)
If used, was considered helpful, n (%, N responses) 1 (50, 2)
Contraceptive pills/patch/ring 162 (55.7)
If used, was considered helpful, n (%, N responses) 51 (32.7, 156)
Exercise, yoga or pilates 131 (45.0)
If used, was considered helpful, n (%, N responses) 38 (30.4, 125)
Hormonal therapy for endometriosis 27 (9.3)
If used, was considered helpful, n (%, N responses) 10 (40, 25)
Herbal medicine 27 (9.3)
If used, was considered helpful, n (%, N responses) 8 (32, 25)
Homeopathic medicine 14 (4.8)
If used, was considered helpful, n (%, N responses) 3 (25, 12)
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TABLE 31 Participant characteristics (continued )
Participant characteristics Value
Massage 80 (27.5)
If used, was considered helpful, n (%, N responses) 32 (42.7, 75)
Meditation or relaxation exercises 57 (19.6)
If used, was considered helpful, n (%, N responses) 22 (40, 55)
Strong painkillers 237 (81.4)
If used, was considered helpful, n (%, N responses) 137 (60.9, 225)
Nerve blocks 5 (1.7)
If used, was considered helpful, n (%, N responses) 2 (40, 5)
Non-prescription medicine 68 (23.4)
If used, was considered helpful, n (%, N responses) 26 (41.3, 63)
Nutrition/diet 90 (30.9)
If used, was considered helpful, n (%, N responses) 28 (33.7, 83)
Physiotherapy 27 (9.3)
If used, was considered helpful, n (%, N responses) 5 (19.2, 26)
Psychological (talking) therapy 20 (6.9)
If used, was considered helpful, n (%, N responses) 6 (33.3, 18)
TENS 12 (4.1)
If used, was considered helpful, n (%, N responses) 6 (55.5, 11)
Other 28 (9.6)
If used, was considered helpful, n (%, N responses) 15 (57.7, 26)
Menstrual history
Age at menarche, mean (SD, n) 12.8 (1.7, 290)
Currently having menstrual periods, n (%, N responses) 252 (86.9, 290)
Pelvic pain with periods in at 3 months, n (%, N responses)
No 13 (5.2)
Occasionally (with 1 in 3 of my periods) 19 (7.6)
Often (with 2 in 3 of my periods) 32 (12.9)
Always (every period) 185 (74.3)
Missing 42
Pelvic pain at times other than with periods or sexual intercourse in the last 3 months,
n (%, N responses)
223 (90.6, 246)
If yes, pain before period, n (%, N responses) 197 (88.3, 223)
If yes, pain after period, n (%, N responses) 145 (66.1, 221)
Period regularity, n (%)
Regular, I know when to expect my period 89 (35.9)
Fairly regular, my period starts within a few days of when I expect 75 (30.2)
Irregular, I cannot predict when my period will start 53 (21.4)
I have bleeding on and off all the time 31 (12.5)
Missing 43
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TABLE 31 Participant characteristics (continued )
Participant characteristics Value
Period heaviness, n (%)
Light 28 (11.2)
Moderate 76 (30.3)
Heavy 95 (37.9)
Bleed through protection 52 (20.7)
Missing 40
Duration of period (days), mean (SD, n) 5.3 (2.0, 244)
Average interval between periods (days), mean (SD, n) 28.0 (12.3, 211)
Clots in menstrual flow, n (%, N responses) 198 (80.5, 246)
Pain on day flow starts, n (%, N responses) 53 (22.2, 239)
If no, how many days before flow, mean (SD, n) 4.3 (3.3, 152)
Previous diagnoses, n (%)
Endometriosis 76 (26.7)
Adhesions 20 (7.0)
Fibroids 35 (12.3)
Adenomyosis 10 (3.5)
Uterine polyps 10 (3.5)
Ovarian cysts 105 (36.8)
Appendicitis 29 (10.2)
Hernia 10 (3.5)
Infertility or low fertility 25 (8.8)
Uterine or bladder prolapse 2 (0.7)
Vulva pain/vulvodynia 8 (2.8)
Irritable bowel syndrome 49 (17.2)
Nerve entrapment in pelvis/pudendal neuropathy 1 (0.4)
Fibromyalgia 7 (2.5)
Painful bladder syndrome (interstitial cystitis) 12 (4.2)
Sexually transmitted infection 36 (12.7)
Female genital mutilation/cutting 2 (0.7)
Previous tests
Previous cervical screening test, n (%, N responses) 229 (79, 290)
If test performed, outcome, n (%)
Normal 210 (92.5)
Abnormal 17 (7.5)
Missing 2 (0.9)
Previous chlamydia test, n (%, N responses) 202 (70.4, 287)
If test performed outcome, n (%)
Negative for chlamydia 176 (87.1)
Positive for chlamydia and treated 21 (10.4)
Positive for chlamydia, not treated 0 (–)
Missing 5 (2.4)
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TABLE 31 Participant characteristics (continued )
Participant characteristics Value
Previous investigations/operations, n (%)
Previous investigations/operations
Laparoscopy 80 (27.5)
Cystoscopy 16 (5.5)
Colonoscopy 36 (12.4)
Hysteroscopy 24 (8.3)
MRI 30 (10.3)
Laparotomy 9 (3.1)
Transvaginal ultrasound 199 (68.4)
Transabdominal ultrasound 220 (75.6)
Nerve transmission test 1 (0.3)
Allergy tests 20 (6.9)
Other 7 (2.4)
Contraceptive user, n (%) 172 (71.4)
Of those using contraception, method(s) used
Female sterilisation (clips) 9 (5.2)
Female sterilisation (implants) 1 (0.6)
Male partner sterilisation 11 (6.4)
Contraceptive pill 71 (41.3)
Mini pill 12 (7.0)
Injection 3 (1.7)
Patch 1 (0.6)
Implant 10 (5.8)
Levonorgestrel-releasing intrauterine system 19 (11.1)
Condom 67 (39.0)
Diaphragm/cap 1 (0.6)
Vaginal ring –
Natural method 7 (4.1)
Obstetric history
Fertility, n (%)
Currently trying to get pregnant, n (%, N responses) 36 (14.8, 242)
Of those trying to get pregnant, n (%)
Trying for < 1 year 8 (22.2)
Trying for > 1 year 28 (77.8)
Pregnancies, n (%)
Number of times been pregnant previously
0 113 (40.0)
1 46 (16.0)
2 51 (18.0)
3 33 (12.0)
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TABLE 31 Participant characteristics (continued )
Participant characteristics Value
4 20 (7.0)
≥ 5 19 (7.0)
Missing 9
If at least one previous pregnancy, outcome
Live birth
0 38 (22.4)
1 41 (24.2)
2 58 (34.3)
3 23 (13.6)
4 5 (2.9)
≥ 5 1 (0.6)
Missing 3 (1.8)
Termination
0 110 (65.1)
1 47 (27.8)
2 8 (4.7)
3 3 (1.8)
4 –
≥ 5 –
Missing 1 (0.6)
Stillbirth
0 158 (93.5)
1 7 (4.1)
2 1 (0.6)
3 –
4 1 (0.6)
≥ 5 –
Missing 2 (1.2)
Miscarriage
0 112 (66.3)
1 35 (20.7)
2 10 (5.9)
3 3 (1.8)
4 4 (2.4)
≥ 5 3 (1.7)
Missing 2 (1.2)
If at least one live birth, route of delivery
Vaginal
0 79 (47.6)
1 27 (16.3)
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TABLE 31 Participant characteristics (continued )
Participant characteristics Value
2 41 (24.7)
3 14 (8.4)
4 4 (2.4)
≥ 5 1 (0.6)
Caesarean section (planned)
0 151 (91.0)
1 10 (6.0)
2 4 (2.4)
3 1 (0.6)
4 –
≥ 5 –
Caesarean section (emergency)
0 135 (80.8)
1 26 (15.6)
2 5 (3.0)
3 –
4 1 (0.6)
≥ 5 –
Forceps/ventouse
0 146 (88.0)
1 18 (10.8)
2 2 (1.2)
3 –
4 –
≥ 5 –
Did any of the following occur during pregnancy, labour or just after giving birth (yes)
Abdominal pain (other than labour contractions) 56 (37)
Perineal tear 53 (35)
Episiotomy 37 (25)
Pelvic girdle pain 26 (17)
Interventions for peri-partum haemorrhage 23 (15)
Participant-reported questionnaires
Pelvic Pain and Urgency/Frequency Patient Symptom Scale
Summary score (points) (SD, n) 13.3 (5.5, 167)
Assessment of sexual activity
Section I, n (%)
Are you currently married or having an intimate relationship with someone? 238 (83)
Have you changed your sexual partner in the last 6 months? 24 (8)
Do you engage in sexual activity with anyone at the moment? 222 (78)
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TABLE 31 Participant characteristics (continued )
Participant characteristics Value
Section II, n (%)
I am not sexually active at the moment because
I do not have a partner at the moment 37 (60)
I am too tired 6 (10)
My partner is too tired 1 (2)
I am not interested in sex 10 (16)
My partner is not interested in sex 3 (5)
I have a physical problem that makes sexual relations difficult or uncomfortable 13 (22)
My partner has a physical problem that makes sexual relations difficult or uncomfortable 1 (2)
Other reason 13 (22)
Section III
Pleasure score (0 =worst outcome, 18= best outcome) (SD, n) 7.4 (4.5, 104)
Discomfort score (0=worst outcome, 6= best outcome) (SD, n) 3.1 (1.7, 204)
Habit score (0 = less than usual, 1= the same as usual, 2= somewhat more than usual, 3=much more
than usual) (SD, n)
2.2 (0.8, 213)
BFI score
Extraversion (0 =worst outcome, 10= best outcome), mean (SD, n) 7.1 (2.0, 283)
Agreeableness (0 =worst outcome, 10= best outcome), mean (SD, n) 7.6 (1.8, 284)
Conscientiousness (0 =worst outcome, 10= best outcome), mean (SD, n) 8.4 (1.6, 279)
Neuroticism (0 =worst outcome, 10= best outcome), mean (SD, n) 6.2 (2.1, 286)
Openness (0 =worst outcome, 10 = best outcome), mean (SD, n) 6.9 (1.6, 282)
Pain Catastrophizing Scale
Over the last month, how much have you been affected by your pain (0 = least affected, 20=worst
affected), mean (SD, n)
–
Of all the problems and stresses in your life, how does your pain compare in importance? (0 = just one
of many problems, 10= the most important thing), mean (SD, n)
–
Depression (6 =worst outcome, 0= best outcome), mean (SD, n) 2.2 (1.8, 289)
Rumination (16 =worst outcome, 0= best outcome), mean (SD, n) 8.5 (4.8, 285)
Magnification (12 =worst outcome, 0 = best outcome), mean (SD, n) 5.4 (3.4, 284)
Helplessness (24 =worst outcome, 0= best outcome), mean (SD, n) 11.6 (6.4, 284)
EQ-5D-3L
Summary score (–0.59 =worst outcome, 1.0 = best outcome) (SD, n) 0.6 (0.3, 286)
Health state (0 =worst outcome, 100 = best outcome) (SD, n) 63.4 (19.4, 270)
ICECAP
Capabilities, as a measure of well-being (0 =worst outcome, 1.0 = best outcome) (SD, n) 0.3 (0.2, 198)
BFI, Big Five Inventory; TENS, transcutaneous electrical nerve stimulation.
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Appendix 2 Additional results from the
diagnostic study
TABLE 32 Accuracy estimates for establishing the absence of any gynaecological cause against laparoscopy and the
EIP assessment without MRI findings
Reference standard
Laparoscopy assessment
of absence of any
gynaecological cause
EIP A assessment of
absence of any
gynaecological cause
EIP B assessment of
absence of any
gynaecological cause
Features of absence of any
gynaecological cause in the MRI
report
Yes No Yes No Yes No
Yes 16 33 Yes 26 23 Yes 27 22
No 59 179 No 130 108 No 126 112
p-value (Fisher’s exact test) p = 0.3 p= 0.9 p = 0.9
Accuracy estimates (95% CI) Sens= 21.3 (12.7 to 32.3)
Spec = 84.4 (78.8 to 89.0)
LR+ = 1.4 (0.8 to 2.3)
LR–= 0.9 (0.8 to 1.1)
DOR = 1.5 (0.8 to 2.9)
Sens = 16.7 (11.2 to 23.5)
Spec = 82.4 (74.8 to 88.5)
LR+ = 0.9 (0.6 to 1.6)
LR– = 1.0 (0.9 to 1.1)
DOR = 0.9 (0.5 to 1.7)
Sens = 17.7 (12.0 to 24.6)
Spec = 83.6 (76.2 to 89.4)
LR+ = 1.1 (0.6 to 1.8)
LR–= 1.0 (0.9 to 1.1)
DOR = 1.1 (0.6 to 2.0)
DOR, diagnostic odds ratio; LR+, likelihood ratio (positive); LR–, likelihood ratio (negative); Sens, sensitivity; Spec, specificity.
TABLE 33 Accuracy estimates for establishing the absence of any gynaecological cause against laparoscopy and EIP
with MRI findings
Reference standard
Laparoscopy assessment
of absence of any
gynaecological cause
EIP A assessment of
absence of any
gynaecological cause
EIP B assessment of
absence of any
gynaecological cause
Features of absence of any
gynaecological cause in the MRI
report
Yes No Yes No Yes No
Yes 55 93 Yes 88 60 Yes 88 60
No 20 119 No 68 71 No 65 74
p-value (Fisher’s exact test) p < 0.0001 p= 0.08 p= 0.03
Accuracy estimates (95% CI) Sens= 73.3 (61.9 to 82.9)
Spec = 56.1 (49.2 to 62.9)
LR+ = 4.7 (3.3 to 6.6)
LR–= 0.3 (0.2 to 0.5)
DOR = 14.9 (8.4 to 26.6)
Sens = 56.4 (48.3 to 64.3)
Spec = 54.2 (45.3 to 62.9)
LR+ = 1.2 (0.9 to 1.5)
LR– = 0.8 (0.6 to 1.0)
DOR = 1.5 (0.9 to 2.4)
Sens = 57.5 (49.3 to 65.5)
Spec= 55.2 (46.4 to 63.8)
LR+ = 0.4 (0.3 to 0.6)
LR–= 1.5 (1.3 to 1.8)
DOR = 0.3 (0.2 to 0.4)
DOR, diagnostic odds ratio; LR+, likelihood ratio (positive); LR–, likelihood ratio (negative); Sens, sensitivity; Spec, specificity.
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TABLE 35 Accuracy of treating gynaecologist’s diagnosis before and after laparoscopy
Confidence score
Pre-index data diagnosis Pre-index data and laparoscopy report
EIP A judgement: absence
of any gynaecological
cause of pain, n (%)
Likelihood
ratio (95% CI)
EIP A judgement: absence
of any gynaecological
cause of pain, n (%)
Likelihood ratio
(95% CI)Yes No Yes No
7–10 62 (40.0) 37 (28.2) 1.5 (1.1 to 2.1) 81 (53.6) 4 (3.1) 17.6 (6.6 to 46.6)
4–6 60 (38.7) 34 (26.0) 1.5 (1.1 to 2.1) 26 (17.2) 18 (13.7) 1.3 (0.7 to 2.2)
0–3 33 (21.3) 60 (45.8) 0.5 (0.3 to 0.7) 44 (29.1) 109 (83.2) 0.4 (0.3 to 0.5)
Total 155 131 p*= 0.0002 151 131 p*< 0.0001
p*, p-value computed from a chi-squared test for trend.
TABLE 34 Accuracy of independent gynaecologist’s diagnosis before and after MRI
Confidence score
Pre-index data diagnosis Pre-index data and MRI report diagnosis
EIP A judgement: absence
of any gynaecological
cause of pain, n (%)
Likelihood
ratio (95% CI)
EIP A judgement: absence
of any gynaecological
cause of pain, n (%)
Likelihood ratio
(95% CI)Yes No Yes No
7–10 53 (34.0) 43 (32.8) 1.0 (0.7 to 1.4) 77 (49.4) 44 (33.6) 1.5 (1.1 to 2.0)
4–6 86 (55.1) 69 (52.7) 1.0 (0.8 to 1.3) 49 (31.4) 47 (35.9) 0.9 (0.6 to 1.2)
0–3 17 (10.9) 19 (14.5) 0.8 (0.4 to 1.4) 30 (19.2) 40 (30.5) 0.6 (0.4 to 1.0)
Total 156 131 p*= 0.5 156 131 p*= 0.004
p*, p-value computed from a chi-squared test for trend.
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Appendix 3 Economic evaluation sensitivity
analyses
The distributions used in the PSA for the economic model are shown in Table 36.
TABLE 36 Distributions used in the PSA for all scenarios
Parameter Distribution Alpha Beta
% of eligible women who receive a laparoscopy when offered Beta 287 20
% of eligible women who receive a MRI when offered Beta 287 35
% of women who have a therapeutic laparoscopy during the same procedure
as a diagnostic laparoscopy
Beta 92 20
% of women who receive a second therapeutic laparoscopy during a separate
procedure following their first therapeutic laparoscopy
Beta 30 82
Prevalence (negative, positive for therapeutic laparoscopy, other treatment) Dirichlet (164,112,11)
Proportion of women who require other treatment who have fibroids
(remainder of women have adenomyosis)
Beta 3 8
Time for consultant and nurse to conduct baseline examination Gamma 1 0.33
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